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Abstract: Astronauts are exposed to considerable doses of space radiation during long-term
space missions. As complete shielding of the highly energetic particles is impracticable, the
cellular response to space-relevant radiation qualities has to be understood in order to develop
countermeasures and to reduce radiation risk uncertainties. The transcription factor Nuclear
Factor κB (NF-κB) plays a fundamental role in the immune response and in the pathogenesis of
many diseases. We have previously shown that heavy ions with a linear energy transfer (LET)
of 100–300 keV/µm have a nine times higher potential to activate NF-κB compared to low-LET
X-rays. Here, chemical inhibitor studies using human embryonic kidney cells (HEK) showed that
the DNA damage sensor Ataxia telangiectasia mutated (ATM) and the proteasome were essential
for NF-κB activation in response to X-rays and heavy ions. NF-κB’s role in cellular radiation
response was determined by stable knock-down of the NF-κB subunit RelA. Transfection of a RelA
short-hairpin RNA plasmid resulted in higher sensitivity towards X-rays, but not towards heavy ions.
Reverse Transcriptase real-time quantitative PCR (RT-qPCR) showed that after exposure to X-rays
and heavy ions, NF-κB predominantly upregulates genes involved in intercellular communication
processes. This process is strictly NF-κB dependent as the response is completely absent in RelA
knock-down cells. NF-κB’s role in the cellular radiation response depends on the radiation quality.
Keywords: nuclear factor κB; RelA; linear energy transfer; heavy ion; space mission; cytokines;
chemokines; cellular radiation response
1. Introduction
Exposure to galactic cosmic radiation which consists of protons, α-particles and heavier nuclei is
a major risk factor for long-term human space missions. On the International Space Station (ISS), the
effective dose rate quantified by human phantom experiments amounted to 550–570 µSv/d inside the
station and 690–720 µSv/d during extravehicular activities [1,2]. During a mission to Mars, astronauts
will accumulate considerable doses of galactic cosmic radiation of about 1 Sv [3,4]. Due to mass
limitations for spacecraft and production of secondary particles in shielding material, the radiation
exposure cannot simply be avoided by radiation shielding of the spacecraft [5]. The potential space
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radiation risks are cancer and non-cancer effects such as cataract formation [6,7] and degenerative
effects in the central nervous and cardiovascular system [8,9]. Furthermore, acute effects may arise
after exposure to a solar particle event during a situation of insufficient shielding [10,11].
Although heavy nuclei only make up about 2% of the fluence in space, they will account for
much of the biological consequences due to their higher linear energy transfer (LET) [12]. Traversal
of heavy nuclei through cellular structures produces ionization tracks along their path, resulting
in the formation of complex DNA damage [13] which elicits the DNA damage response (DDR)
leading to several possible outcomes, such as cell cycle arrest, allocating additional time for repair
of the damaged DNA, cellular senescence or different types of cell death, if the damage is too
severe and cannot be repaired [14] (reviewed in Hellweg et al., IJPT, in press). The transcription
factor Nuclear Factor κB (NF-κB) is involved e.g., in regulation of proliferation, immune system
development and performance, inflammation and apoptosis [15]. The activation NF-κB by ionizing
radiation [16] was discovered early after its first description [17]. Exposure to accelerated heavy
ions (95 MeV/nucleon-MeV/n-Ar, LET 272 keV/µm) resulted in much stronger activation of NF-κB
in human cells than X-ray exposure [18]. The NF-κB activation by energetic carbon ions (35 and
75 MeV/n, LET 73 and 33 keV/µm, respectively) was comparable to the effect induced by X-rays [19],
suggesting a narrow peak in the LET dependence of NF-κB activation. This was confirmed by studies
with a large set of heavy ions, covering a LET range of ~30–10,000 keV/µm, which revealed a maximal
NF-κB activation by heavy ions in a LET range of ~91–272 keV/µm [20]. This LET range is highly
relevant for space radiation exposure of astronauts [21]. Furthermore, during the last fifteen years,
in addition to the canonical and alternative pathways of NF-κB activation, a direct pathway for its
activation by genotoxic stress was discovered. This sub-pathway involves a nuclear to cytoplasmic
shuttle that transports the information from radiation-induced DNA double strand breaks in the cell
nucleus to the cytoplasm where NF-κB is sequestered in its inactive state [22,23]. The released NF-κB
translocates to the nucleus and binds to κB DNA motifs (NF-κB response elements, NRE) initiating
gene transcription. NRE have been identified in the promoter or enhancer regions of a number of
growth factors, antiapoptotic molecules, cytokines and adhesion molecules involved in fibrosis and
inflammation [24,25]. Our recent work showed that the expression level of several NF-κB-dependent
cyto- and chemokines after heavy ion exposure follows a similar LET dependence as NF-κB activation
itself [26].
As NF-κB is involved in regulation of apoptosis and immune and inflammatory responses,
its activation may influence the outcome of a heavy ion exposed cell (cellular survival/death, cell cycle
arrest, DNA repair) and therefore might be relevant for late effects which might occur after prolonged
low-dose exposure during an interplanetary mission and might be potential pharmacological target
for mitigation of the radiation response. The aim of this work was to analyze the role of the NF-κB
pathway in the cellular response to exposure to space-relevant high-LET radiation.
In order to enable monitoring of radiation-induced NF-κB activation, a previously developed
reporter cell line, HEK-pNF-κB-d2EGFP/Neo L2 [27], was used. This cell line harbors a plasmid which
reports NF-κB-dependent transcriptional activation in response to various stimuli simply by expressing
the destabilized variant of enhanced green fluorescent protein (d2EGFP) [28] when activated NF-κB
binds to its synthetic promoter which contains four NRE tandem copies. By measuring the yields of
green fluorescence of the reporter protein it is possible to quantify NF-κB-dependent transcriptional
activation in response to stimuli.
To assess the role of NF-κB in the cellular response to heavy ion exposure, besides the use of
chemical inhibitors, the expression of the NF-κB subunit p65/RelA was downregulated by stable
transfection of the reporter cell line with a RelA short-hairpin RNA (shRNA RelA). Growth, cell cycle
progression, survival and gene expression after ionizing radiation exposure (low- and high-LET) were
compared for cells with normal and reduced RelA expression. Due to limited beam time availability,
heavy ion experiments were restricted to high-dose rate exposures.
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2. Results
The role of the NF-κB pathway in the cellular response to low and high-LET radiation was studied
in human embryonic kidney cells.
2.1. Kinetics of NF-κB Activation
The kinetics of NF-κB-dependent expression of the reporter gene d2EGFP was determined after
exposure to 10.9 Gy X-rays, 10.9 Gy carbon ions or 10 ng/mL tumor necrosis factor α (TNF-α) (Figure 1).
The high dose was chosen as X-rays are a weak activator of NF-κB. The activation was strongest in
response to TNF-α and reached a maximum after 20 h. After irradiation, the maximum was reached
already after 16 h. Two days after carbon ion exposure and after addition of TNF-α, NF-κB dependent
d2EGFP expression was still detectable in ~30% and ~50% of the cells, respectively. Activation by
X-rays was transient and reached normal levels within one day.
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HEK-pNF-κB-d2EGFP/Neo L2 cells were irradiated with X-rays (200 kV, linear energy transfer (LET) 
~0.3–3 keV/µm) or 13C-ions (75 MeV/n, LET 34 keV/µm) or incubated with 10 ng/mL TNF-α as a 
positive control. At different time points after induction, cells were trypsinated and fixed with 3.7% 
formaldehyde. d2EGFP expression was analyzed by flow cytometry. 
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and Heavy Ion Exposure 
To determine whether ATM and the proteasome are involved in NF-κB activation by different 
ionizing radiation qualities, specific inhibitors were used. First, cytotoxicity of the inhibitors and the 
inhibitory concentration were determined (Figure 2A). 2 µmol/L MG-132 were sufficient to 
completely suppress TNF-α induced NF-κB activation (Figure 2B). The ATM inhibitor KU-55933 had 
no effect on TNF-α triggered NF-κB activation, as it is not involved in the classical pathway (Figure 
2C). Therefore, the concentration was determined from the literature (10 µmol/L). Treatment with 2 
µmol/L MG-132 or 10 µmol/L KU-55933 completely abolished the X-ray-induced NF-κB activation 
(Figure 2D). Compared to X-rays in the same dose range, exposure with argon ions resulted in a 
higher NF-κB activation with a saturation at ~8 Gy (Figure 2E). Additionally, this activation was 
completely suppressed by KU-55933 and by MG-132 (Figure 2E). 
Figure 1. Kinetics of Nuclear Factor κB (NF-κB)-dependent destabilized enhanced green fluorescent
protein (d2EGFP) expression after treatment with tumor necrosis factor α (TNF-α), X-rays and
carbon ions, as detected in stably transfected human embryonic kidney cells (HEK) cells from
d2EGFP reporter gene expression controlled by a promoter containing four NF-κB response elements
(NRE) and the minimal promoter of thymidine kinase (TK) (HEK-pNF-κB-d2EGFP/Neo clone L2).
HEK-pNF-κB-d2EGFP/Ne L2 cells were irradiated with X-rays (200 kV, linear energy transfer (LET)
~0.3–3 keV/µm) or 13C-ions (75 M V/ , LET 34 keV/µm) or incubated with 10 ng/mL TNF-α as a
positive control. At different time point fter inducti n, cells were trypsinated and fixed with 3.7%
formaldehyde. d2EGFP expression was analyzed by flow cytometry.
2.2. Ataxia Telangiectasia Mutated (ATM) and the Proteasome Are Required for NF-κB Activation by X-rays
and Heavy Ion Exposure
To determine whether ATM and the proteasome are involved in NF-κB activation by different
ionizing radiation qualities, specific inhibitors were used. First, cytotoxicity of the inhibitors and
the inhibitory concentration were determined (Figure 2A). 2 µmol/L MG-132 were sufficient to
completely suppress TNF-α induced NF-κB activation (Figure 2B). The ATM inhibitor KU-55933
had no effect on TNF-α triggered NF-κB activation, as it is not involved in the classical pathway
(Figure 2C). Therefore, the concentration was determined from the literature (10 µmol/L). Treatment
with 2 µmol/L MG-132 r 10 µmol/L KU-55933 complet ly abolished the X-ray-induced NF-κB
activation (Figure 2D). Compared to X-rays in the same dos range, exposure with argon ions resulted
in a higher NF-κB activation with a saturation at ~8 Gy (Figure 2E). Additionally, this activation was
completely suppressed by KU-55933 and by MG-132 (Figure 2E).
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Figure 2. Ataxia telangiectasia mutated (ATM) and the proteasome are required for NF-κB activation by
low and high LET radiation. Means and standard error (SE) of two to three independent experiments
with three replicates each are shown. The viability of HEK-pNF-κB-d2EGFP/Neo L2 cells after
treatment with increasing concentrations of ATM inhibitor KU-55933 and the proteasome inhibitor
MG-132 was determined by means of the 3-(4,5-dimethylthiazole-2-yl-2,5- iph nyltetra- zolium
bromide (MTT) test 100 h after adding the inhibitor. The dotted line i icates 80% relative viability (A);
the effect of MG-132 (B) a KU-55933 (C) on TN -α-induced activation of the NF-κB pathway was
determined in HEK-pNF-κB-d2EGFP/Neo L2 cells preincubated with the inhibitor for 1 h before
addition of 10 ng/mL TNF-α. Cells were detached and fixed with 3.7% formaldehyde after 18
h. NF-κB-dependent d2EGFP-expression was measured by flow cytometry. The suppression of
radiation-induced activation of the NF-κB pathway by KU-55933 and MG-132 was determined in
HEK-pNF- κB-d2EGFP/Neo L2 cells after exposure to X-rays (200 kV, LET ~0.3–3 keV/µm, (D) and
36Ar-ions (95 MeV/n, LET 270 keV/µm, (E) cells were preincubated with the inhibitor for 1 h and
subsequently irradiated. After 18 h, NF-κB-dependent d2EGFP-expression was measured by flow
cytometry. The percentage of d2EGFP(+) cells was normalized to the mock-irradiated control. For 36Ar
ions, doses (Gy) were calculated from fluences (P/cm2) according to Equation (1) (Section 4.5.3.).
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2.3. Effect of RelA Knock-Down on NF-κB-Dependent Gene Expression
The reporter gene and inhibitor experiments had shown that ATM and the proteasome are
involved in ionizing radiation-induced NF-κB activation. For specific downregulation of the NF-κB
pathway, the key component RelA was knocked down by stable transfection of four different RelA
shRNA plasmids carrying a hygromycin resistance gene. The knock-down level in polyclonal
hygromycin-resistant cells resulting from transfection with RELA-1 and -4 plasmids was above 40%
(Figure 3A). Clones from these populations were grown, and three clones reached a knock-down
level above 70%. The clone with the highest knock-down was selected for further experiments and
designated HEK shRNA RelA (Figure 3B, arrow).
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investigating gene expression with RT2 ProfilerTM PCR arrays, a proper RNA and cDNA quality was 
confirmed. ** Five times less RelA mRNA in the HEK shRNA RelA cells compared to the 
HEK-pNF-κB-d2EGFP/Neo L2 cells results in a reduction of the expression level of 100% to 20% with a 
downregulation of 80%. This knock-down level is in line with the 87% observed using the RelA primer 
assays before. The complete data set is shown in Table A3. 
Figure 3. Verification of RelA knock-down on messenger RNA (mRNA) level after transfection of
HEK-pNF-κB-d2EGFP/Neo L2 cells with RelA short-hairpin RNA (shRNA) plasmids. Polyclonal
hygromycin-resistant cells resulting from transfection with the shRNA plasmids RELA-1 to 4 were
grown in petri dishes and total RNA was collected after 3 days (A). Clones were grown from the
cell population transfected with the shRNA plasmids RELA-1 and 4, as these were most effective in
suppressing RelA expression, and the knock-down level of RelA mRNA was determined in these
clones (B). R lA mRNA xpression was determined by real-time RT-qPCR. Means and SD of three
independent experiments with each three replicates are shown.
As the selected HEK shRNA RelA clone showed a remaining RelA expression of ~17%, the effect
of this residual level on basal expression (Table 1) and on TNF-α-induced expression of NF-κB target
genes (Table 2) was analyzed.
Table 1. Basal gene expression in HEK shRNA RelA cells compared to the original cell line
HEK-pNF-κB-d2EGFP/Neo L2 using the RT2 Profiler PCR array *.
Gene Symbol Description Relative Gene Expression (µ± SE)
CCL5 Chemokine (C-C motif) ligand 5 15.57 ± 8.77
CCND1 Cycli D1 −2.99 ± 0.05
IL8/CXCL8 Interleukin-8 −8.12 ± 5.20
GADD45B Growth arrest and DNA-damage-inducible, beta 3.63 ± 1.08
JUN Jun oncogene 4.96 ± 1.85
RELA V-rel reticuloendotheliosis viral oncogene omolog A −4.93 ± 0.02 **
* The table shows all genes from both the customized and the NF-κB signaling array, that are more than threefold
up- or downregulated in HEK shRNA RelA cells compared to HEK-pNF-κB- d2EGFP/Neo L2 c lls. 162 gen s were
investigated. Mean (µ) and standard error (SE) of the expression level were calculated from up to five independent
experiments with untreated cells. Prior to investigating gene expression with RT2 ProfilerTM PCR arrays, a proper
RNA and cDNA quality was confirmed. ** Five times less RelA mRNA in the HEK shRNA RelA cells compared
to the HEK-pNF-κB-d2EGFP/Neo L2 cells results in a reduction of the expression level of 100% to 20% with a
downregulation of 80%. This knock-down level is in line with the 87% observed using the RelA primer assays
before. The complete data set is shown in Table A3.
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Table 2. TNF-α * induced gene expression in HEK shRNA RelA cells (RelA k.d.) compared to the
original cell line HEK-pNF-κB-d2EGFP/Neo L2 (HEK wt) using the RT2 Profiler PCR array **.
Gene Symbol Description Relative Gene Expression
HEK wt RelA k.d.
BIRC3 Baculoviral IAP repeat containing 3 4.76 ± 0.98 2.03 ± 0.47
C3 Complement component 3 5.97 ± 1.39 1.97 ± 0.57
CCL2 Chemokine (C-C motif) ligand 2 3.04 ± 0.24 −1.28 ± 0.09
CCL11 Chemokine (C-C motif) ligand 11 3.73 ± 1.51 1.84 ± 0.57
CCL5 Chemokine (C-C motif) ligand 5 4.79 ± 1.79 29.02 ±12.66
CD69 CD69 molecule 3.37 ± 0.23 −1.15 ± 0.04
CD83 CD83 molecule 5.68 ± 0.82 1.67 ± 0.08
CXCL1 Chemokine (C-X-C motif) ligand 1 47.46 ± 11.75 −1.05 ± 0.08
CXCL10 Chemokine (C-X-C motif) ligand 10 23.38 ± 5.72 −1.18 ± 0.06
CXCL2 Chemokine (C-X-C motif) ligand 2 18.29 ± 3.92 1.72 ± 0.33
EXO1 Exonuclease 1 1.97 ± 0.67 −4.92 ± 0.02
IL1R2 Interleukin 1 receptor, type II 4.02 ± 1.29 1.71 ± 0.30
IL8/CXCL8 Interleukin-8 17.83 ± 5.19 2.39 ± 0.50
IRF1 Interferon regulatory factor 1 3.16 ± 0.40 1.29 ± 0.11
MMP9 Matrix metallopeptidase 9 3.34 ± 0.61 2.01 ± 0.37
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 11.88 ± 1.66 1.22 ± 0.04
PLAU Plasminogen activator, urokinase 3.35 ± 0.57 2.64 ± 0.58
PTGS2 Prostaglandin-endoperoxide synthase 2 3.99 ± 0.53 2.17 ± 0.39
TNF Tumor necrosis factor 60.95 ± 12.42 3.40 ± 0.54
TNFRSF1B Tumor necrosis factor receptor superfamily, member 1B 1.49 ± 0.34 4.13 ± 2.29
* Cells were treated for 6 h with 10 ng/mL TNF-α. ** The table shows all genes from both, the customized and
the NF-κB signaling array, that are more than threefold up- or downregulated (in bold) in HEK shRNA RelA
cells compared to HEK-pNF-kB-d2EGFP/Neo L2 cells. 162 genes were investigated. The mean of the fold up- or
downregulation was calculated from up to two independent experiments with untreated cells. Prior to investigating
gene expression with RT2 ProfilerTM PCR arrays, a proper RNA and cDNA quality was confirmed. The complete
data set is shown in Table A4.
As expected, RelA mRNA was downregulated. In addition, cyclin D1 and IL-8 expression were
reduced in HEK shRNA RelA cells compared to the parental cell line (Table 1). The expression of
CCL5, GADD45B and Jun was increased in cells with RelA downregulation.
Incubation with TNF-α induced a large set of NF-κB target genes in HEK cells, with highest
expression of TNF, IL8, CXCL1, 2 and 10, and NF-kappa-B inhibitor alpha (NFKBIA) (Table 2).
RelA knock-down nearly completely abolishes the TNF-α-induced expression of all these target genes
except CCL5. EXO1 which is not a NF-κB target gene is downregulated when RelA is knocked down.
Furthermore, NF-κB-dependent reporter gene expression was determined. The basal level of
d2EGFP expression was unchanged compared to the parental cell lines and to cells stably transfected
with a shRNA control plasmid with a random sequence (Figure 4A). TNF-α- and X-ray-induced
d2EGFP expression were significantly reduced in HEK shRNA RelA cells compared to the parental
cell line as well as to the shRNA control cell line (p ≤ 0.05, Figure 4A). The reactions of the parental
cell line and the shRNA control cell line were not significantly different in no case based on a p = 2α
level of <0.05. Carbon ion induced d2EGFP expression was completely abolished (Figure 4B).
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ions (B). HEK-pNF-κB-d2EGFP/Neo L2 cells, cells stably transfected with the shRNA control vect r
(HEK shRNA control) or the RelA shRNA plasmid (HEK shRNA RelA) were seeded in petri dishes,
grown for two days, and expos d to X-rays (200 kV, LET ~0.3–3 keV/µm), incubated with 10 ng/mL
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2.4. Growth of RelA Knock-Down Cells
In order to determine whether RelA knock-down affects basic cellular functions such as
growth, cell numbers were counted during a gro th period of 10 days. HEK shRNA RelA cells
showed a prolonged lag phase compared to HEK-pNF-κB-d2EGFP/Neo clone L2 cells (Figure 5).
Once proliferation starts, both cell lines grow with the same velocity.
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2.5. Survival of RelA Knock-Down Cells After X-ray and after Heavy Ion Exposure
The survival curves after exposure of HEK-pNF-κB-d2EGFP/Neo clone L2 cells and HEK shRNA
RelA cells were of curvilinear shape (Figure 6). The curve of the RelA knock-down cells is significantly
steeper, indicating a higher radiosensitivity. The D0 indicating the dose necessary to reduce survival of
HEK cells to 37% is 1.12 Gy for the parental cell line compared to 0.82 Gy for the RelA knock-down
cells (Table 3).
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Figure 6. Clonogenic survival of HEK cells with RelA knock-down compared to the parental cells after
X-irradiation (200 kV). HEK-pNF-κB-d2EGFP/Neo L2 and HEK shRNA RelA cells were irradiated,
incubated and colonies were fixed after 14 to 21 days (means ± SE of 7–13 independent experiments
with six replicates each).
Table 3. Parameters of the survival curves *.
D0 (Gy) n Dq (Gy)
Significance
Level for D0
Radiation
Quality
LET
(keV/µm) HEK wt RelA k.d. HEK wt RelA k.d. HEK wt RelA k.d. p = 2α
X-rays 0.3–3 1.20 ± 0.05 0.76 ± 0.04 1.31 ± 0.84 2.43 ± 1.06 0.33 ± 0.71 0.68 ± 0.33 <0.005
12C 10 1.03 ± 0.14 0.91 ± 0.22 1.17 ± 0.34 1.64 ± 1.15 0.15 ± 0.36 0.34 ± 0.71 0.6006
28Si 55 0.47 ± 0.05 0.38 ± 0.04 1.28 ± 0.34 1.31 ± 0.12 0.12 ± 0.14 0.10 ± 0.12 0.1923
58Ni 175 0.53 ± 0.02 0.61 ± 0.04 1.0 ± 0.26 0.73 ± 0.26 0.0 ± 0.12 −0.19 ± 0.19 0.0607
36Ar 271 0.72 ± 0.09 0.68 ± 0.08 0.82 ± 0.36 1.11 ± 0.29 −0.14 ± 0.27 0.08 ± 0.19 0.8371
* For cellular survival data the parameters D0 and n of the dose effect curve were calculated by regression analysis
(survival versus dose) and fitted to the equation S = 1 − (1 – expD/Do)n. The comparison of different survival
curves were performed by Student’s t-test of the regression coefficients. A p = 2α level of <0.05 was considered as
significant. Comparison of two regression lines for HEK-pNF-κB-d2EGFP/Neo L2 and HEK shRNA RelA cells is
based on the hypothesis (σ2yx)1 6= (σ2yx)2 for D0; P, probability.
High-LET radiation exposure of HEK cells results in purely exponential survival curves (Figure 7).
Based on energy dose, heavy ions with an LET of 55 keV/µm are most efficient in cell killing (Figure 7A),
while radiation qualities with an LET above or below this range are less efficient in cell killing
(Figure 7A,B). The D0 first decreases to 0.47 Gy for silicon ions, then increases with increasing LET to
0.72 Gy for argon ions (Table 3).
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Figure 7. Clonogenic survival of HEK cells with RelA knock-down compared to the parental
cells after exposure to heavy ions of diffent LET (A), linear energy transfer (LET) < 100 keV/µm,
(B) LET > 100 keV/µm). HEK-pNF-κB-d2EGFP/Neo L2 and HEK shRNA RelA cells were irradiated,
incubated and colonies were fixed after 14–21 days (means ± SE of 1–2 independent experiments with
each six replicates).
2.6. Induction of NF-κB Target Gene Expression by Exposure to Different Radiation Qualities
As NF-κB was weakly activated by X-rays and act ted by heavy ions to a higher extent,
depend nt on LET, but o ly for X-rays, a reduction of survival in case of RelA downregulation
was observed, the expression of 88 NF-κB target genes was profiled 6 h after exposure to X-rays and
heavy ions (Table 4).
The expression of chemokines and cytokines was upregulated by low- and high-LET radiation at
higher doses. Exposure to 0.5 Gy X-rays or Ti ions did not significantly up-regulate the expression of
the investigated NF-κB target genes. The chemokine and cytokine expression was in general higher
after exposure to 4 Gy Ti ions compared to 4 Gy X-rays. The highest expression levels were reached for
CXCL10 and TNF.
Adhesion molecules such as VCAM-1 and a costimulatory factor (CD83) were also induced.
Components of the NF-κB pathway such as NFKB2 and the inhibitor NFKBIA were upregulated by
the two radiation qualities.
RelA knock-down inhibited the ionizing radiation-induced NF-κB target gene expression except
for TNFRSF1B.
2.7. Secretion of TNF-α and IL-8 after X-Irradiation
The secretion of the cytokines GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12(p70)
and TNF-α was determined using a multiplex ELISA. Only IL-8 and TNF-α reached values above the
quantification limit of the assay.
In ubation with TNF-α resulted in trong secretion of IL-8 by HEK-pNF-κB-d2EGFP/Neo L2
cells within 12 h, and the IL-8 concentration in the cell culture supernatants further increased within
the next 36 h (Figure 8A). High doses of X-rays (8 and 16 Gy) are required to induce significant IL-8
secretion 12 h after irradiation, and this secretion is further enhanced at later time points (24 h and 48 h).
In HEK shRNA RelA cells, the level of IL-8 secretion in mock-irradiated cells (0 Gy) is lower compared
to HEK-pNF-κB-d2EGFP/Neo L2 cells, and only the highest X-ray dose (16 Gy) and incubation with
TNF-α provoke a very slight time-dependent increase in IL-8 secretion (Figure 8B).
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Table 4. Relative gene expression in HEK-pNF-κB-d2EGFP/Neo L2 (HEK wt) and HEK shRNA RelA (RelA k.d.) cells after irradiation * using the RT2 Profiler PCR
array **. The complete data sets are shown in Tables A5 and A6.
Radiation Quality X-rays 48Ti ions
Dose (Gy) 0.5 4.0 8.0 0.5 4.0
Gene Symbol/Cell Line HEK wt RelA k.d. HEK wt RelA k.d. HEK wt RelA k.d. HEK wt RelA k.d. HEK wt RelA k.d.
CCL5 −1.42 ± 0.24 1.55 ± 0.68 3.68 ± 1.53 2.07 ± 0.90 3.34 ± 1.40 −1.47 ± 0.30 −1.97 ± 0.17 −1.89 ± 0.23 −1.56 ± 0.22 1.22 ± 0.53
CD83 −1.01 ± 0.03 1.12 ± 0.06 2.47 ± 0.08 1.67 ± 0.08 3.75 ± 0.18 2.27 ± 0.11 1.25 ± 0.04 1.09 ± 0.05 4.37 ± 0.14 1.42 ± 0.07
CXCL1 1.04 ± 0.20 1.06 ± 0.09 3.57 ± 0.56 1.52 ± 0.12 6.96 ± 1.01 2.02 ± 0.16 1.01 ± 0.19 −1.48 ± 0.05 7.55 ± 1.44 1.21 ± 0.10
CXCL2 −1.35 ± 0.13 −1.04 ± 0.19 2.33 ± 0.33 1.55 ± 0.30 3.01 ± 0.40 1.29 ± 0.25 1.30 ± 0.22 1.11 ± 0.21 3.48 ± 0.59 1.00 ± 0.19
CXCL10 −1.10 ± 0.16 1.05 ± 0.08 4.68 ± 0.60 2.23 ± 0.16 14.58± 2.57 2.04 ± 0.15 −1.27 ± 0.14 −1.30 ± 0.06 6.70 ± 1.20 −1.15 ± 0.06
CXCL8/IL8 −1.73 ± 0.19 1.20 ± 0.19 2.42 ± 0.66 1.38 ± 0.22 3.74 ± 0.86 1.01 ± 0.16 1.38 ± 0.44 −1.26 ± 0.13 6.10 ± 1.96 1.44 ± 0.23
NFKB2 1.01 ±0.12 1.09 ± 0.18 2.93 ± 0.33 1.48 ± 0.24 4.07 ± 0.45 1.62 ± 0.26 −1.25 ± 0.09 −1.02 ± 0.16 2.52 ± 0.29 1.04 ± 0.17
NFKBIA −1.07 ± 0.08 −1.13 ± 0.10 2.65 ± 0.34 1.47 ± 0.17 4.26 ± 0.40 1.69 ± 0.19 −1.11 ± 0.08 1.05 ± 0.12 3.55 ± 0.31 1.47 ± 0.17
TNF 1.01 ± 0.11 1.08 ± 0.05 5.10 ± 0.99 1.17 ± 0.06 12.90 ± 1.72 1.15 ± 0.05 1.08 ± 0.12 −1.26 ± 0.04 6.72 ± 0.76 −1.12 ± 0.04
TNFRSF1B −1.81 ± 0.16 −2.15 ± 0.26 1.02 ± 0.22 4.10 ± 2.28 1.11 ± 0.22 2.39 ± 1.33 1.07 ± 0.30 2.88 ± 1.60 −2.04 ± 0.14 −2.65 ± 0.21
VCAM1 −1.27 ± 0.20 1.08 ± 0.05 4.24 ± 1.56 1.17 ± 0.06 2.94 ± 0.87 1.15 ± 0.05 −1.77 ± 0.15 −1.26 ± 0.04 −1.10 ± 0.24 −1.12 ± 0.04
* Exposure to X-rays or 48Ti-ions (1000 MeV/n, LET 108 keV/µm). ** The table shows all genes from the NF-κB signaling array, that are more than threefold up- or down-regulated (in
bold) in irradiated cells compared to mock-irradiated cells. The mean of the fold up- or downregulation was calculated from up to two independent experiments with untreated cells.
Prior to investigating gene expression with RT2 ProfilerTM PCR arrays, a proper RNA and cDNA quality was confirmed. ACTB, B2M, GAPDH, HPRT1 and RPLP0 were used as reference
genes to normalize the results.
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NF-κB-activation by TNF-α or ionizing radiation, the reduced RelA levels in the knock-down cells 
Figure 8. Kinetics of IL-8 and TNF-α secretion of HEK-pNF-κB-d2EGFP/Neo L2 (A,C) and HEK
shRNA RelA cells (B,D) after X-irradiation. The supernatants were collected at the indicated time
points. The TNF-α and IL-8 content of the supernatants was determined by means of a multiplex ELISA.
Mean and standard error of three independent experiments with duplicate cytokine determination
are shown.
TNF-α secretion increased 12 h after exposure of HEK-pNF-κB-d2EGFP/Neo L2 cells to 16 Gy
X-rays and remained levated during the investi ated time period without furth r signifi ant increase
(Figure 8C). The total amount was much lower compared to IL-8. For HEK shRNA RelA cells,
TNF-α secretion r mained within background levels for all applied doses and incubation periods
(Figure 8D). TNF-α secretion induced by incubation with TNF-α is not shown, as the added TNF-α
was present in the supernatants and disguised the TNF-α secretion of the cells.
3. Discussion
In this study, we show that knock-down of the NF-κB subunit RelA results in sensitization of
HEK cells towards low-LET X-rays, but not towards heavy ions in a LET range of 10 to 272 keV/µm.
It was previously demonstrated that heavy ions in the LET range of 91 to 272 keV/µm strongly
activate NF-κB [20]. The NF-κB activation by low- a d high-LET ionizing radiation was shown
to be ATM dependent. Furthermore, IκB-degradati by the proteasome is essential for i nizing
radiation-induced NF-κB-activation.
RelA knock-down also influenced cell proliferation, resulting in a prolonged lag phase, but
it did not impact the proliferation rate once the exponential growth phase was reached. Without
NF-κB-activation by TNF-α or ionizing radiation, the reduced RelA levels in the knock-down cells
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changed the expression of only a few NF-κB target genes (CCND1, CXCL8, JUN, TNF). After incubation
with TNF-α or irradiation, the upregulation of CXCL1, 2, 8 and 10, NFKBIA and TNF was strongly
reduced in RelA knock-down cells.
3.1. Activation of the NF-κB Pathway by Different Radiation Qualities
Our first study examining the effects of heavy ions on the NF-κB pathway revealed that high-LET
argon ions (272 keV/µm) activated the sequence of all events in the NF-κB pathway from DNA binding
via transcription to protein translation and maturation [18]. The study of the LET dependence of
this cellular response to heavy ion exposure disclosed that indeed the maximal potency to activate
NF-κB dependent d2EGFP gene expression in HEK cells occurs at 272 keV/µm (argon ions) have [20].
In accordance with the results presented here, other authors using a DNA binding assay report nuclear
translocation NF-κB after exposure of normal human monocytes (MM6 cells) after exposure to 0.7 Gy
of 56Fe ions [29]. Activation of NF-κB was mediated through phosphorylation of IκBα via subsequent
proteasomal degradation. The study on iron ion effects on monocytes revealed only binding of NF-κB
to its consensus sequence of 5′-GGGGACTTTCC-3′, transcriptional activation itself was not shown.
Also in vivo, NF-κB activation was observed in the heart and bone marrow of mice one week,
one month and six months after exposure to 300 MeV/n 28Si ions (LET 77 keV/µm) [30]. This clearly
indicates that high-LET ion exposure induces rapid and persistent NF-κB activation in vitro and
in vivo.
3.2. NF-κB Activation by Ionizing Radiation Is ATM Dependent
KU-55933 is specific for ATM with respect to inhibition of other related kinases such as
DNA-dependent protein kinase (DNA-PK) or phosphatidylinositol 3′-kinase (PI3K) which required a
~200 times higher concentration for their inhibition [31]. Results showed that while it was not possible
to suppress TNF-α-induced NF-κB activation, KU-55933 suppressed ionizing radiation-induced NF-κB
activity completely. Increasing doses of X-rays and 36Ar ions were used to induce NF-κB, showing its
dose and LET dependency, as the percentage of d2EGFP(+) cells increased with increasing doses and
36Ar ions had a higher impact on d2EGFP-dependent NF-κB expression than X-rays.
These results support the assumption that ionizing radiation, including high-LET heavy ions,
activates the genotoxic stress induced NF-κB pathway and proves that NF-κB activation induced by
ionizing radiation is strictly ATM dependent. ATM foci form quickly in the nuclei of human cells
after exposure to carbon or iron ions and are believed to facilitate or initiate DNA double strand break
(DSB) repair by Non-Homologous Endjoining (NHEJ) and Homologous Recombination (HR) [32,33].
ATM was shown to be activated in human cells to a higher extent by carbon ions (LET 290 keV/µm)
than by low-LET γ-rays [34]. This stronger ATM phosphorylation after heavy ion exposure might be
important for the strong NF-κB activation that was observed in the LET range of 90–300 keV/µm.
In contrast, TNF-α induced NF-κB activation was not impaired by KU-55933, as ATM is not
involved in the classical pathway, which is activated by TNF-α.
3.3. IκB Degradation by the Proteasome Is Essential for TNF-α and Ionizing Radiation-Induced NF-κB Activity
Within non-cytotoxic concentrations (viability above 80%), MG-132 suppressed TNF-α- and
ionizing radiation-induced NF-κB activity, showing that IκB degradation by the proteasome is an
essential step in both, the genotoxic stress and the TNF-α-induced pathway. However, it has to
be considered, that disturbing proteasome functions with MG-132 leads to the loss of regulation of
essential functions within the cell and these chemical inhibitors are not NF-κB specific.
3.4. Role of RelA in Cell Proliferation
Downregulation of RelA prolonged the lag phase. Furthermore, cells required a longer recovery
period after freezing and thawing, indicating a role of RelA in cell proliferation. This is supported by the
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observation that transfection of NF-κB/RelA antisense oligodeoxynucleotide reduces the proliferation
of SGC-7901 gastric cancer cells [35] and that siRNA-mediated RelA knock-down decreased the
proliferation ability of human esophageal squamous cell cancer (ESCC) EC9706 cells [36]. In tumor
cells, the inhibiting effect of RelA knock-down seems to be much more pronounced compared to
HEK cells. This might be explained by a constitutive NF-κB activation in many tumors, e.g., some
gliomas [37] and hepatomas [38], which is then suppressed. In breast cancer cells, transfection of RelA
shRNA reduced proliferation [39].
The reduced expression of cyclin D1 (−3.0) is a possible explanation for the effects of RelA
knock-down on proliferation, as RelA and JunD were shown to cooperate to activate the proximal κB
site of the cyclin D1 promoter in presence of serum [40]. Cyclin D1 regulates the cyclin-dependent
kinases CDK4 or CDK6, the activity of which is required for cell cycle G1/S transition. This connection
of NF-κB, cyclin D1 and proliferation was also found in neural stem or progenitor cells (NSCs,
NPCs) [41] and fibroblasts [42]. Upregulation of the activated protein 1 (AP-1) family member Jun
(5.0) in HEK shRNA RelA cells might be a regulatory mechanism to compensate for the RelA loss,
as c-Jun affects cell proliferation, migration and invasion and, like NF-κB, actively participates in
tumorigenesis [43].
3.5. Role of RelA in Clonogenic Survival after Exposure to Different Radiation Qualities
As activation of the NF-κB pathway is supposed to play a role in the negative regulation of
apoptosis, survival of cells with residual DNA damage might thus be favored after irradiation. Even if
this happens only in rare cases after ionizing radiation exposure, it might result in initiation or
promotion of cancer from such wise affected cells. Cellular responses which may be related to better
survival of exposed cells would contribute considerably to astronauts’ radiation risk, especially at low
doses when transient induction of genes involved in maintaining DNA fidelity and in modulating
cell cycle progression and cell death would occur [44]. As heavy ion exposure strongly activated
NF-κB, we examined whether NF-κB gives HEK cells a survival advantage after heavy ion exposure.
For this purpose, expression of the NF-κB subunit RelA was downregulated by stable transfection of
RelA shRNA.
The colony forming ability test showed that HEK cells were more sensitive to X-irradiation
when RelA was downregulated. Such sensitization to X-rays was also observed with chemical
NF-κB inhibitors, e.g., the sesquiterpene lactone parthenolide, an IκB kinase (IKK) inhibitor,
inhibited constitutive and radiation-induced NF-κB binding activity in p53 null PC-3 cells and
enhanced their X-ray sensitivity by a dose modification factor of 1.7 [45]. RelA knock-out murine
embryonic fibroblasts (MEF p65−/−) were 1.3-fold more sensitive towards X-rays than the p65+/+
cells [46]. In many cancer cell types, NF-κB inhibition sensitized the cells to ionizing radiation [47–50].
In these MEF p65−/− cells, the killing effect of UVB radiation was lower compared to MEF
wildtype cells (p65+/+) [51]. Therefore, in contrast to ionizing radiation, loss of RelA conferred a strong
resistance to UVB-induced cell death which was accompanied by reduced Gadd45 gene expression [51].
In contrast to the sensitization to X-rays by RelA knock-down, the sensitivity to heavy ion
exposure was equal or only slightly different for cells with and without RelA over a wide range of LET
(10–271 keV/µm). This indicates that RelA and heavy ion induced NF-κB activation does not procure
a survival advantage for the exposed cells. This might be explained by other pro-death signals of the
heavy ion exposure. Interestingly, in human hematopoietic stem and progenitor cells (HSPC) and
peripheral blood lymphocytes (PBL), inhibition of NF-κB activation by expression of a super-repressor
variant of IκBα (IκBα-SR) altered DNA double-strand-break repair [52]. IκBα-SR expression reduced
homologous DSB repair in PBL by 33% [52]. NHEJ of DNA DSBs was compromised in HSPC and PBL
(reduction to 37% and 52%, respectively) [52]. These measurements were performed on enzymatically
induced DNA DSBs, results for low- or even high-LET radiation-induced DSBs are not yet available.
Nevertheless, reduced DNA DSB repair in case of NF-κB repression or down-regulation might play a
role for survival after ionizing radiation exposure. Delayed or incomplete repair might override other
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NF-κB induced survival signals. Another explanation for the missing effect of RelA knockdown might
be the high-LET which is in the range of the highest observed biological efficiency. The cell killing
effect in the LET range of 100–200 keV/µm is already very high, so that disturbed cellular signaling
pathways might not be able to further increase cell killing. This was observed for the pro-apoptotic
p53 in some cell systems: apoptosis was independent of the p53 status [53,54].
Comparing ionizing radiation and chemotherapeutics such as the topoisomerase II inhibitor
doxorubicin, knock-down of RelA by siRNA increased the killing effect of doxorubicin in HepG2
cells [38]. The authors of this publication explain the increased killing of hepatoma cells by lower
NF-κB-mediated expression of multi-drug resistance (MDR1) gene [38]. A mechanism based on
MDR1 is not likely to influence survival after ionizing radiation. In nude mice bearing HeLa cervical
cancer xenografts, downregulation of p65 via photothermal transfection of p65 siRNA increased
irinotecan-induced tumor apoptosis [55].
Furthermore, the NF-κB target gene expression profile might be different for low- and high-LET
radiation exposure and might give an explanation for the different role in the cellular radiation
response. Therefore, the expression of 88 target genes was determined after X-ray and heavy ion
exposure. Genes that are regulated more than threefold and at the same time are controlled by RelA
are discussed below.
3.6. Role of RelA in the Expression of NF-κB Target Genes after Exposure to Different Radiation Qualities
NF-κB target genes that are induced after irradiation affect intercellular communication and many
of them are proinflammatory. e.g., TNF-α activates inflammation by inducing a proinflammatory
cytokine cascade, mediated through expression of IL8 [56]. Incubation with TNF-α induces the
expression of a larger subset of genes than low- or high-LET irradiation at a dose of 4 Gy (Figure 9A).
TNF, CXCL1 and −10 are upregulated by TNF-α, 4 Gy X-rays and 4 Gy Ti ions. A higher X-ray dose
(8 Gy) increased the overlap in the subset of induced NF-κB target genes (Figure 9B). The gene subsets
show overlap with those determined in osteosarcoma cells [57].
The overlapping gene expression in HEK-pNF-κB- d2EGFP/Neo L2 cells after TNF-α and
radiation treatment was not observed in RelA knock-down cells, confirming the role of the NF-κB
subunit RelA in the expression of these genes.
After TNF-α treatment HEK-pNF-κB-d2EGFP/Neo L2 cells but not in HEK shRNA RelA cells
showed a clear upregulation of C-X-C motif (CXC, C stands for cysteine, X for any other amino
acid) chemokine genes, including CXCL1, CXCL10, CXCL2 (MIP-2) and CXCL8 (IL8). The CXC
chemokines belong to one group of small cytokines, which, when they are are secreted by infected
cells act as chemoattractants inducing chemotaxis or migration especially of neutrophils, which are
the first responders during inflammation to migrate towards site of inflammation. Additionally, in
wound healing the increased chemokine concentration of damaged cells results in attracting cells to
site of damage. Loss of chemokine induction is a serious impairment for the organism as it leads to
dysfunctional cell migration and wound healing deficiency. The essential role of TNF in the early
induction of chemokines and subsequent recruitment of leukocytes have been shown using models
of mycobacterial infection [58] as induction of chemokines and cellular recruitment were delayed in
TNF−/− cells. Animal studies show that CXCL2 was upregulated in murine tumors after exposure to
carbon ions (290 MeV/n, LET 50 keV/µm) [59].
As expected, TNF-α treatment induced high upregulation (60.0) of TNF, as TNF-α, after being
released as a response to immunological stimuli, acts as a positive autocrine feedback signal to augment
NF-κB activation [60]. In the knock-down cell line, no upregulation of TNF was observed, as NF-κB is
a key transcription factor involved in the synthesis of TNF-α [61].
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transcription of the inhibitor IκB, thus leading to its own inactivation and subsequent termination of 
the response [62]. Other studies showed that NFKBIA was also upregulated in six human malignant 
melanoma cell lines after carbon ion exposure (290 MeV/n, LET 50 keV/µm) [63]. 
Only three of the genes upregulated in HEK-pNF-κB-d2EGFP/Neo L2 cells were induced by 
TNF-α in the knock-down cell line: CCL5, TNF and TNFRSF1B. For the latter two genes, the 
induction factor was much lower compared to the RelA proficient cell line. Instead, downregulation of 
one NF-κB target gene was observed, EXO1. Exonuclease 1 (EXO1) is involved in DNA damage 
signaling [64]. 
The target gene array, investigating 88 genes after X- and 48Ti ion irradiation, showed that 
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expression increases with increasing doses. Further, the degree of regulation is stronger after 4 Gy of 
48Ti ion exposure than after X-irradiation of the same dose. 
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Figure 9. Diagr m showing the expr i n of NF-κB target genes by HEK cells 6 h after exposure to
10 ng/mL T F-α, 4 Gy X-rays or 4 Gy Ti ions (A) and after exposure to 10 ng/mL TNF-α or 8 Gy
X-rays (B) VCAM-1 is in parentheses as its expression is just below the threshold of threefold induction.
Upregulation of NFKBIA (encoding IκBα) in the original cell line was expected as well, as in
addition to increasing the transcription of cytokines and adhesion proteins, NF-κB also increases the
transcription of the inhibitor IκB, thus leading to its own inactivation and subsequent termination of
the response [62]. Other studies showed that NFKBIA was also upregulated in six human malignant
melanoma cell lines after carbon ion exposure (290 MeV/n, LET 50 keV/µm) [63].
Only three of the genes upregulated in HEK-pNF-κB-d2EGFP/Neo L2 cells wer induced by
TNF-α in the knock-down cell lin : CCL5, TNF and TNFRSF1B. For the latter two ge es, the i duction
factor was much lower compared to th RelA proficient cell line. Instead, downregulation of one NF-κB
target gene was observed, EXO1. Exonuclease 1 (EXO1) is involved in DNA damage signaling [64].
The target gene array, investigating 88 genes after X- and 48Ti ion irradiation, showed that
NF-κB-dependent gene expression does not only depend on dose, but also on LET, complementing
our recently published study [26] and studies with Caenorhabitidis elegans [65]. The extent of gene
expression increases with increasing doses. Further, the degree of regulation is stronger after 4 Gy of
48Ti ion exposure than after X-irradiation of the same dose.
In HEK-pNF-κB-d2EGFP/N o L2 cells, the set of genes, that has already been shown to be
upregulated after TNF-α tr atme t, was likewise upregulated after exposure to X-rays and heavy ions.
It includes CXC chemokines, TNF and NFKBIA which encodes the NF-κB inhibitor IκBα. This shows
that expression of these genes is activated not only by the classical NF-κB pathway, but also the
genotoxic stress induced, independent of the radiation quality.
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In this work, both low- and high-LET radiation exposure resulted in upregulation of TNF, and with
higher LET, the upregulation was stronger. Interestingly, in the tibial marrow of Fe ion (600 MeV/n,
LET 174 keV/µm) irradiated mice, no significant increase in TNF expression was found three days
after exposure to 2 Gy, and only a slight increase after 2 Gy γ-irradiation which remained elevated
through day three after irradiation [66].
Especially the CXC chemokines are strongly upregulated, in case of CXCL10 up to 14.6 fold
after irradiation with 8 Gy X-rays. None of the genes that are upregulated at higher doses in the
original cell line exceeds the threshold of 3 after irradiation with 0.5 Gy of both, X-rays and 48Ti ions.
Though, after 4 Gy of X-rays, CXC chemokines reach expression values of 2.3 to 4.7 fold. For the same
dose, these genes are expressed up to 7.6 fold after 48Ti ion irradiation.
CCL5 has chemotactic activity for monocytes and basophils and binds to chemokine receptors
CCR2 and CCR4. It was upregulated by high doses of X-rays. Such an upregulation was also observed
in vivo in the bone marrow of C57BL/6J mice exposed to 2 Gy γ-rays and is suggested to promote
ostoclastogenesis [66].
Apart from the genes expressed after both, TNF-α treatment and irradiation, additional genes
are upregulated only upon X-irradiation, not after heavy ion exposure, proving the relation between
radiation quality or LET and gene expression. These genes include CCL5, NFKB2, and VCAM1.
NFKB2 codes for the NF-κB subunit p100, which is involved in the non-canonical NF-κB pathway.
It is processed to p52. This element of the non-canonical pathway seems to be upregulated only
by X-rays and not by heavy ions. The RelB:p52 dimer was shown to confer radio-resistance to
prostate cancer cells by upregulating the expression of the antioxidant enzyme manganese superoxide
dismutase (MnSOD) [67–70]. An upregulation of RelB expression 8 h after X-ray exposure (0.1, 1 Gy)
was also observed in a three-dimensional skin tissue model [71].
The different gene expression profile after 48Ti ion irradiation indicates distinct responses,
depending on radiation quality, eventually including different repair mechanisms, as indicated in
the survival curves in this work. These genes are expressed after X-irradiation, but not after 48Ti
ion exposure. The missing expression of the protecting RelB gene after heavy ion exposure might
be another explanation why RelA knock-down results in higher X-ray sensitivity, but not in higher
heavy ion exposure sensitivity: Its protecting effect ceases to exist in HEK shRNA RelA cells after
X-irradiation, but it is not induced after heavy exposure even in case of normal RelA levels.
CD83 expression was activated by 4 Gy Ti ions, TNF-α and 8 Gy X-rays. It is one of the central
regulatory molecules in immune functions with anti-tumor effects [72]. It acts as a co-stimulator
during activation of T-cells by antigen-presenting cells and is therefore essential for the induction
of the adaptive immune response. NF-κB regulates inducible CD83 gene expression in activated T
lymphocytes during an adaptive immune response [73]. Increased expression of this costimulatory
molecule indicates that exposure to ionizing radiation does not only induce inflammation as a
prominent innate immune response via proinflammatory cytokines such as TNF-α and via chemokines,
but also induces selected steps towards activation of adaptive immunity.
In absence of RelA, only TNFRSF1B is upregulated after X-ray exposure. TNFRSF1B encodes for
the TNF receptor TNF-R2. It was shown that TNFRSF1B receptor signaling resulted in the activation
of anti-apoptotic survival proteins [74]. At the same time, TNFRSF1B promotes TNF-α induced
apoptosis [75]. Baseline plasma TNFRSF1B, a marker of inflammation and a soluble TNF antagonist,
was significantly associated with an increased risk of human colorectal cancer [76]. TNF-α bound to
TNFRSF1B recruits intracellular adaptor proteins to activate multiple signal transduction pathways
including NF-κB [77]. The activation of NF-κB in intestinal epithelial cells by TNF-α through
TNFRSF1B receptor signaling has been previously linked to carcinogenesis. Silencing TNFRSF1B
increased apoptosis [74]. However, NF-κB interferes with apoptotic signals at various levels. The best
example is found in the TNF-R1 pathway [78]. It is therefore not certain whether increased apoptosis
results from pro-apoptotic TNFRSF1A signaling. An upregulation of TNFRSF1B expression 8 h after
X-ray exposure (0.1, 1 Gy) was also observed in a three-dimensional skin tissue model [71].
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Overall, results revealed the outstanding role of NF-κB and its subunit RelA in cytokine expression
after exposure to low- and high-LET radiation and therefore in the “sterile inflammation” after radiation
exposure [57]. In contrast to other studies with cancer cells, no radiation-induced upregulation of
antiapoptotic genes above the threefold threshold was found. BIRC3 encoding cIAP2 was upregulated
2.0 and 2.5 times after exposure to 4 and 8 Gy X-rays, respectively. In differentiated thyroid cancer
(DTC) cells, incubation with (131)I-induced NF-κB activation, and knock-down of p65 by siRNA
transfection increased (131)I-induced cell killing [79]. This effect was explained by lower expression of
the antiapoptotic NF-κB target genes XIAP, cIAP1, and Bcl-xL when p65 expression was downregulated
by siRNA [79].
3.7. Role of RelA in IL-8 and TNF-α Production for Survival after Exposure to Different Radiation Qualities
IL8 (Interleukin 8, CXCL8) was severely downregulated (−8.1) in HEK shRNA RelA cells.
In presence of RelA, IL-8 secretion was strongly induced by TNF-α and high X-ray doses. This cytokine
is part of the CXC chemokine family and acts as proinflammatory mediator, further activating
proinflammatory cytokines in a positive feedback loop. It attracts and activates neutrophils [80],
causing them to migrate towards the site of infection. It was shown for several cell types, that the
NF-κB binding site is essential for transcription of IL-8 [81,82]. Interleukin 8 secretion was also
increased in response to oxidative stress, mediated by TNF-α, which further induces RelA-binding to
the binding site of the IL-8 promoter [56]. In HTori-3 cells, a human thyroid epithelial cell line, exposed
to either a non-toxic radiation dose (0.1 Gy) or a slightly toxic dose (0.2 Gy) from iron ions (1 GeV/n),
IL-8 expression was altered [83]. In organotypic cultures of oral mucosa irradiated with X-rays or
carbon ions, both radiation qualities increased the release of IL-8, with a saturation at 4 Gy for early
time points, and higher early increases (4 h) after carbon ion exposure in the spread-out Bragg peak
(SOBP, track-averaged LET ~50 keV/µm) [84,85]. The IL-8 release remained increased for two days
after carbon ion exposure (2, 4, 10 Gy) [84].
TNF-α secretion was increased after higher doses of X-rays (16 Gy), while its mRNA level was
enhanced already at a dose of 4 Gy.
3.8. Implications for Countermeasure Development
Although caution should be taken to directly translate in vitro data to a clinical setting and the
doses used here are quite high, the study suggests that due to NF-κB activation by heavy ion exposure
astronauts would be prone to “sterile inflammation” in relevant target organs. Indeed, Parihar et al.
found increased numbers of activated microglia in the perirhinal cortex of rodents exposed to low
doses of helium and other space-relevant accelerated ions, indicating neuroinflammation [86,87].
For ensuring astronauts’ health, countermeasures have to be developed which could rely not
necessarily on therapeutically applied drugs but on natural inhibitors of the proteasome or other
regulating factors in the NF-κB pathway as dietary supplements. The proteasome inhibitor MG132
which was used in this study is not such a candidate as it inhibits multiple proteases in addition to the
proteasome. Furthermore, at least in tumor cells, treatment with MG-132 prior to irradiation lead to
radiosensitization [88], which is an effect exploited for tumor therapy with the proteasome inhibitor
bortezomib [89].
Possible candidates for protection against chronic inflammation could be members of the
triterpenoid family, which inhibit the NF-κB pathway at various sites [90,91]. Additionally, in our
earlier studies, capsaicin, an active component of the red pepper (Capsicum), partially inhibited NF-κB
activation in HEK cells in a non-toxic concentration range [92]. However, NF-κB is a central element
of various physiological functions and its inhibition might be associated with various side effects.
Therefore, evaluation of its target genes that are upregulated by radiation exposure might lead to more
specific toeholds to mitigate radiation-induced inflammation.
For high-dose exposure that could occur during a large solar particle event, activation of the
NF-κB pathway might increase the survival of, e.g., bone marrow stem cells and intestinal epithelial
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cells and thereby ameliorate the acute radiation syndrome. For this purpose, Toll-like receptor 5 (TLR5)
agonists were developed based on bacterial flagellin and successfully tested in animal models [93].
3.9. Conclusions
RelA is essential for cytokine and chemokine expression after exposure to both, low- and high-LET
radiation and it thereby shapes the sterile inflammatory response, which comprises a smaller NF-κB
target gene subset compared to TNF-α treatment. ATM and the proteasome are essential for NF-κB
activation by different radiation qualities. NF-κB confers a survival advantage after X-ray, but not after
heavy ion exposure.
4. Materials and Methods
4.1. Transformation and Preparation of Plasmid DNA
For plasmid propagation, 100 µL of competent E. coli DH5α-cells (Stratagene; Agilent
Technologies, Karlsbrunn, Germany) were transformed with 2 µL of each SureSilencing™ shRNA
Plasmid (~30–50 ng/µL) according to the manufacturer’s protocol. The transformed bacteria were
plated on selective LB-agar plates containing ampicillin (Biochrom GmbH, Berlin, Germany) with
a final concentration of 50 µg/mL for selection and incubated at 37 ◦C over night. For plasmid
preparation, single colonies were cultured for 16 h in 100 mL of LB-medium containing ampicillin
under permanent shaking. For preparation of plasmid DNA the Plasmid Maxi Kit (Qiagen, Hilden,
Germany) was used following the instructions of the manufacturer. For quality control, the optical
density at 260 nm and 280 nm was determined in a spectrophotometer (Nanodrop 2000c, Thermo
Scientific, Langenselbold, Germany). Only preparations with an OD260/OD280 of more than 1.8 were
used for the transfection of human cells.
4.2. Cell Culture
The cell line HEK 293 was established by Graham et al. (1977) from human embryonic kidney
cells immortalized by transfection with sheared fragments of adenovirus type 5 DNA [94]. The cells
contain only the stably integrated region (E1a and E1b genes) of the human adenovirus genome and
do not produce viral particles. Cells were obtained from the American Type Culture Collection (ATCC
CRL-1573; now: LGC Standards, Wesel, Germany). Cloning of the plasmid pNF-κB-d2EGFP/Neo,
stable transfection and selection of an appropriate cell clone (HEK-pNF-κB-d2EGFP/Neo L2) was
already described [27]. HEK-pNF-κB-d2EGFP/Neo L2 and untransfected HEK cells have comparable
radiosensitivity to X-rays and to accelerated carbon ions and show no difference in proliferation [19].
Cells were maintained in α-medium (Biochrom KG, Berlin, Germany) containing 0.6 mg/mL G418
and 10% fetal bovine serum (FBS) at standard conditions (37 ◦C, 95% air and 5% CO2 atmosphere).
Cells were passaged every week and seeded in a cell density of 3 × 104 cells/cm2 in 80 cm2 cell culture
flasks (Nunc, Novodirect, Kehl, Germany). Medium was exchanged after four days. Cell culture
vessels were coated with poly-D-lysine (10 µg/cm2, Sigma-Aldrich Chemie, Steinheim, Germany, in
sterile deionized water) to allow a stronger binding of cells to the substrate. Therefore, the culture
vessels were coated with poly-D-lysine for 15 min at room temperature and subsequently washed
three times with sterile deionized water.
4.3. Stable Transfection
For knock-down of the NF-κB subunit RelA, HEK-pNF-κB-d2EGFP/Neo L2 were stably
transfected with the SureSilencing™ shRNA plasmids RELA-1 to 4 and the control plasmid from
SABiosciences (Frederick, MD, USA). Four of these plasmids encoded different targeting sequences of
RelA mRNA, while the fifths plasmid was a negative control vector containing a scrambled artificial
sequence which did not match any human, mouse or rat gene. HEK-pNF-κB-d2EGFP/Neo L2 cells
were seeded in poly-D-lysine-coated 6-well-plates (Nunc). Transfection was conducted at a cell density
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of ~50%. Therefore, 2 µg of DNA of each vector were mixed with the transfection reagent FuGENE
6® (Roche, Mannheim, Germany) and serum-free α-medium according to the protocol. After three
days of incubation, cells were transferred into ∅ 6 cm culture dishes (Nunc) containing α-medium
with 400 µg/mL hygromycin (US Biological, Salem, MA, USA). After approximately 10 days, cells
were seeded for RNA isolation (Section 4.9.1) to measure the knock-down level of RelA in the mixed
population by real-time quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR).
The strongest knock-down of RelA expression was achieved with the plasmids RELA-1 and RELA-4
(Figure 4A). Therefore, clones grown from single cells of these two cell populations were grown
by seeding 50 cells per microtiter plate containing hygromycin-medium. Cells were incubated for
2–3 weeks until colonies were grown. A single colony was washed with PBS, trypsinized and added to
a 25 cm2 cell culture flask (Nunc) containing 5 mL of hygromycin-medium. When cells had reached
a density of 80–100%, their knock-down level was determined by seeding them in triplicates and
proceeding according to 4.10. In clone 4–9, RelA mRNA expression was reduced by 83.1% and it was
used for further experiments. The selected clone was named HEK shRNA RelA and is characterized
by a RelA knock-down level of 83.1% and a resistance against hygromycin.
4.4. Growth Kinetics
To characterize differences in growth behavior between HEK-pNF-κB-d2EGFP/Neo L2 and
HEK shRNA RelA, both cell lines were seeded with the same cell number (1 × 104 cells/cm2) in
poly-D-lysine-coated 6-well plates. The cell number of one well was determined daily until cells
reached the stationary growth phase.
4.5. Treatment Modalities
For cytokine treatment or irradiation experiments, 3 × 104 cells/cm2 were seeded into suitable
culture vessels freshly coated with poly-D-lysine (10 µg/cm2, Sigma-Aldrich Chemie, Steinheim,
Germany) for 15 min followed by washing with phosphate buffered saline (PBS). For exposure to
TNF-α, X-rays and heavy ions, cells were seeded into 25 cm2 flasks (Iwaki, Dunn Labortechnik
GmbH, Asbach, Germany for GANIL, Nunc for GSI and HIMAC). Cells were incubated for two days
before treatment.
4.5.1. Cytokine Treatment
Human recombinant TNF-α was obtained from Sigma-Aldrich Chemie. TNF-α (final
concentration 10 ng/mL), was dissolved in PBS, and added in serum-containing medium. Cells were
harvested for flow cytometry as described in 0 after different time points. Control dishes
were solvent-treated.
4.5.2. X-Irradiation
X-irradiation was performed at DLR in Cologne using a Gulmay RS225 X-ray source (Xstrahl,
Surrey, UK). Cells were irradiated at room temperature with 200 kV and 15 mA at a dose rate of
~1 Gy/min. To eliminate soft X-rays, a copper filter (thickness 0.5 mm) was used. Cells were irradiated
in petri dishes (Ø 3 or 6 cm). Doses up to 16 Gy were used, with an LET of 0.3–3 keV/µm. Control
dishes were sham-irradiated. Doses were determined using the UNIDOSwebline (PTW, Freiburg,
Germany).
4.5.3. Heavy Ion Exposure
Irradiation with accelerated heavy ions was performed at the “Grand Accélérateur National
d’Ions Lourds” (GANIL, Caen, France), at the GSI Helmholtzzentrum für Schwerionenforschung
GmbH (GSI) in Darmstadt, Germany, or at the Heavy Ion Medical Accelerator in Chiba (HIMAC),
Japan. Characteristics of the applied beams including the LET in water are shown in Table 5.
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Table 5. Characteristics of the heavy ion beams.
Energy (MeV/n) a LET (keV/µm) Penetration Depth (µm) Accelerator
Ion Species Beam on Target b in H2O
Carbon (12C) 400.0 400.0 10.0 272,900 HIMAC
Carbon (13C) 75.0 71.4 34.2 15,120 GANIL
Silicon (28Si) 490.0 490.0 55.0 161,300 HIMAC
Titanium (48Ti) 1000.0 996.9 107.7 319,900 GSI
Nickel (58Ni) 1000.0 996.9 174.5 263,600 GSI
Argon (36Ar) 95.0 83.8 271.5 6336 GANIL
a Mega-electron-Volt/nucleon. b Effective irradiation energy at the cell monolayer. For GANIL beam times energy
losses occur in two detectors, the exit window, ~1 cm air and the bottom of the culture vessel (1200 µm polystyrene
or 25 µm polytetrafluoroethylene foil). For GSI and HIMAC beams energy losses are marginal (only from bottom of
the culture vessel).
Adherent cells were irradiated in sub-confluent stage and in upright position at room temperature.
Therefore, flasks and petri dishes were completely filled with α-medium and closed. Dosimetry was
performed by the staff at the accelerator facilities. Dose rates were adjusted to approximately 1 Gy/min.
At GANIL, dosimetry was performed by the “Centre de recherches sur les Ions, les Matériaux et la
Photonique” (CIMAP)/“Laboratoire d’Accueil en Radiobiologie avec les Ions Accélérés” (LARIA)
staff, yielding the fluence in particles/cm2 (P/cm2) [95]. To convert fluence (F) to the energy dose, the
following formula was applied [96]:
Dose[Gy] = 1.6 × 10−9 × LET[keV/µm] × F[P/cm2] (1)
After irradiation, serum-free α-medium was discarded and cells were further cultivated with
fresh medium containing 10% FBS.
4.6. Cytotoxicity of Chemical Inhibitors
Cytotoxicity of chemical inhibitors KU-55933 and MG-132 was measured by the MTT
assay. Reduction of MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) to
formazan is correlated to the activity of cellular enzymes and measured colorimetrically.
HEK-pNF-κB-d2EGFP/Neo L2 cells were seeded in 96-well plates and incubated with each inhibitor
for 20 and 72 hours. NF-κB was activated by adding TNF-α protected from light. 100% DMSO
was added to one well to measure the background signal. After removing medium, cells were
incubated for 1 h at 37 ◦C with serum-free α-medium containing 0.1 mg/mL MTT. Subsequently,
cells were lysed with DMSO with 10% (w/v) sodium dodecyl sulfate (SDS) and 0.6% (v/v) acetic acid
while shaking them for 20 min with 30 rpm. Finally, absorbance of formazan was measured with
the fluorescence/luminescence microplate reader Lambda Fluoro 320 (MWG Biotech AG, Penzberg,
Germany) at 562 nm. Cell survival was calculated as a ratio of formazan-absorbance of treated vs.
untreated samples after subtraction of the background signal.
4.7. Colony Forming Ability
For investigating cellular survival after exposure to X-rays and heavy ions, cells were seeded and
irradiated as already described. Immediately after irradiation adherent cells were trypsinized and
re-plated in six petri dishes per dose. The cell density for seeding of irradiated cells was adjusted to
compensate for the plating efficiency of the respective cell line and for the anticipated lethal effect of
the treatment in order to allow growth of 40–60 colonies per dish.
After 21 days of incubation without medium change the resulting colonies were fixated and
stained (1 mg/mL crystal violet in 3% formaldehyde solution, Sigma-Aldrich Chemie) and colonies
containing more than 50 cells were counted. The experiments were performed with six dishes per dose
and repeated if beam time was available.
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All data from the irradiated samples were fitted by least-squares linear regression analysis to
lnS = ln(PED/PED=0) versus dose, where the natural logarithm of S is the survival and PE are the
plating efficiencies of treated (PED) or untreated cells (PED=0). Differences in the survival curves
were statistically verified by a two-sided Student’s t-test of the regression lines. A p level of 0.05 was
considered to reflect significance.
4.8. Flow Cytometry
For measurement of d2EGFP, cells were harvested at different time points after radiation or
cytokine treatment by trypsinization and fixed with 4.5 mL cold 3.5% formaldehyde in PBS. For flow
cytometric analysis, cells were centrifuged and resuspended in PBS. Forward and side scatter and green
fluorescence (FL-1) of 20,000 cells from the samples were measured in a FACScan (Becton Dickinson,
San Jose, CA, USA) with an argon laser (488 nm) as excitation source. The markers d2EGFP(−) and
d2EGFP(+) were set by means of untreated and TNF-α treated cells. The percentage of d2EGFP(+) cells
was used as measure of NF-κB-dependent d2EGFP expression.
4.9. Gene Expression Analysis
4.9.1. RNA Isolation
Each sample was seeded in triplicates. At a density of ~50% cells were lysed with RLT buffer
containing 1% 14.3 mol/L β-mercaptoethanol and transferred into an RNase-free Eppendorf tube with
an iced syringe. RNA was isolated using the RNeasy® Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol. As RNA was used for cDNA synthesis and subsequent RT-qPCR, the
additional DNase treatment step was included to eliminate residual genomic DNA. RNA was eluted
in 50 µL RNase-free H2O.
RNA concentration and purity were measured photometric (A260/280) with the NanoDrop 2000c
Spectrometer (Thermo Scientific, Waltham, MA, USA). Additionally, RNA concentration, RNA integrity
(RNA Integrity Number; RIN) and rRNA ratio (28S/18S) were measured by micro-electrophoresis
using the RNA 6000 Nano Assay in the Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara,
CA, USA).
For gene expression analysis with the RT2 Profiler™ PCR Arrays (SABiosciences, Washington,
DC, USA), further RNA quality control with RT2 RNA QC PCR array (SABiosciences) was performed.
4.9.2. cDNA Synthesis
Quality, integrity and quantity of isolated RNA were analyzed. Subsequently, RNA was
transcribed into cDNA using the RT2 First Strand Kit (SABiosciences). A preliminary genomic DNA
elimination step was conducted by incubation of 1 µg total RNA with gDNA Elimination Buffer, as
recommended in the protocol. To detect possible remaining genomic DNA contamination in isolated
RNA samples, one sample lacking reverse transcriptase was used as a negative control. The reaction
mix (4 µL BC 3 (5X RT Buffer), 2 µL PC2 (Primer and External Control Mix 3), 2 µL RE3 (RT Enzyme
Mix 3), 3 µL ddH2O) was incubated at 42 ◦C for 5 min. The RT reaction mix was then added to the
Genomic DNA Elimination Mixture and incubated at 42 ◦C for 15 min. The reaction was stopped by
heating at 95 ◦C for 5 min. cDNA concentration at this stage was 50 ng/µL. Finally, 91 µL of H2O
were added to each 20 µL cDNA synthesis reaction to obtain a final cDNA concentration of 9 ng/µL.
cDNA samples were stored at −20 ◦C.
4.9.3. Setting Up RT-qPCR Validation of Knock-Down-Level
The quantitative real-time PCR reaction mix for one PCR tube was composed referring to the RT2
qPCR Primer Assays protocol (SABiosciences) as follows: 12.5 µL RT2 SYBR Green qPCR Master Mix,
8.5 µL ddH2O, 3 µL Template cDNA (27 ng) and 1 µL 10 µmol/L PCR primer pair stock.
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As a negative control DNA was replaced by H2O. The primer pairs SYBR® Green Human RELA
and SYBR® Green Human HPRT 1 (RT2 qPCR Primer Assay, SABiosciences) were used for targeting
the gene of interest (GOI) RelA and the housekeeping gene (HKG) HPRT (Table 6).
Table 6. RT-qPCR primer pairs * as described in the RT2 qPCR Primer Assay (SABiosciences).
Gene Symbol REF SEQ ACC. # Amplicon Size Melting Temperature
RELA NM_021975.3 65 bp 80.0 ◦C
HPRT1 NM_000194.2 89 bp 76.5 ◦C
* All genes listed are human genes. HPRT, Hypoxanthine phosphoribosyltransferase 1; RELA, V-rel
reticuloendotheliosis viral oncogene homolog A (avian).
4.9.4. Human RT2 Profiler PCR Array
RT2 Profiler™ PCR Arrays (SABiosciences) were used to profile the expression of 88 genes per
sample. Two different arrays were available, with one being customized (PAHS-021), individually
composed of genes of interest of several signaling pathways (Human Cell Cycle, PAHS-020A;
Human NF-κB Signaling Pathway, PAHS-025A; Human p53 Signaling Pathway, PAHS-027A;
Human Apoptosis, PAHS-012A; Human PI3K-AKT Signaling Pathway, PAHS-058A; Human Stress
and Toxicity Pathway Finder, PAHS-003A; Human DNA Damage Signaling Pathway, PAHS-029A;
Human Oxidative Stress and Antioxidant Defense, PAHS-065A) for an initial screening (Table A2)
and one array focusing on genes targeted by NF-κB (human NF-κB target gene array, PAHS-225ZD,
Table A1). An overview of all genes included in these arrays is listed in Appendix A. Overall, 162 genes,
involved in cell cycle control, apoptosis, DNA damage, stress and toxicity and NF-κB signaling were
investigated. Each well of these arrays contains primers for the respective gene.
Only cDNA samples, which had been approved by the RT2 RNA QC PCR Array (SA Biosciences)
to prevent false positive signals by genomic DNA contamination, were used for further analysis.
The RT-qPCR master mix for one 96-well plate was set up according to the RT2 RNA QC PCR Array
protocol using 1350 µL RT2 SYBR Green qPCR Master Mix, 1248 µL ddH2O and 102 µL template
cDNA (9 ng/µL).
Quantitative real-time analysis was performed in the Opticon2 thermocycler starting with an
initial denaturation for 10 min at 95 ◦C, following by 40 cycles (denaturation for 15 s at 95 ◦C, annealing
for 35 s at 55 ◦C, elongation for 30 s at 72 ◦C, plate read), a final incubation for 1 min at 95 ◦C and 2
min at 65 ◦C, and a melting curve from 65–95 ◦C with reads every 0.2 ◦C. The threshold cycle (Ct) was
determined in the amplification plots. Results were analyzed according to the algorithm described in
the RT2 RNA QC PCR Array protocol. It is based on the ∆∆Ct method:
∆Ct = Ct (target gene) − Ct (reference gene) (2)
∆∆Ct = ∆Ct (sample) − ∆Ct (control) (3)
The relative expression of treated sample versus control was calculated by means of Equation (4):
Rate of gene expression = 2−∆∆Ct (4)
In a cautious data interpretation, the threshold for significant up- or downregulation was set to
−3 or +3, respectively, to avoid misinterpretation of physiological fluctuation of mRNA levels.
4.10. Measurement of Cytokine Secretion
To measure the cytokine concentration in the cell culture supernatants (100 µL aliquots, frozen
and stored at −80 ◦C after collection and once thawed, centrifuged for 5 min at a relative centrifugal
field of 300× g) of HEK-pNF-κB-d2EGFP/Neo L2 and HEK shRNA RelA cells, the LUNARISTM
Human 11-Plex Cytokine Kit was used (LHCY-20110S, Ayoxxa Biosystems GmbH, Köln, Germany)
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which is based on beads-on-a-chip technology with a classical sandwich immunoassay principle and a
fluorescence readout. The calibration curve was generated according to the kit handbook. Briefly, seven
standards were prepared by serial dilution (1:4) of the Human Cytokine Standard using Assay Diluent
2. The standard contained the following analytes: GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8,
IL-10, IL-12(p70) and TNF-α. The LUNARISTM BioChips were first washed and the 5 µL of standard,
blank and samples which were diluted 1:2 in Assay Diluent 2 were loaded into the appropriate wells.
After an incubation of at least 3 h at room temperature, the BioChips were washed and 10 µL of
detection antibody solition was added and allowed to incubate for 60 min at RT. The BioChips were
washed again and then 10 µL of Streptavidin-Phycoerythrin (SA-PE) reagent was added. After 30 min
of incubation, the final washing step was performed and the BioChips were air-dried and imaged
using the LUNARISTM Reader (LRS-001). The quantification of the readout was performed using the
LUNARISTM Analysis Suite Software.
4.11. Statistics
Each experiment was repeated up to five times depending on the availability of beam time
with one to six replicates each. In order to account for different numbers of replicates and repeats,
the standard error was calculated. Means, standard errors and significance levels in the t-test were
calculated with Microsoft® Office Excel 2010 (Microsoft Deutschland GmbH, München, Germany).
Regression analyses were performed using SigmaPlot 13.0.
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Abbreviations
AP-1 activated protein 1
ATCC American Type Culture Collection
CIMAP Centre de recherches sur les Ions, les Matériaux et la Photonique
d2EGFP destabilized EGFP
DDR DNA damage response
DNA-PK DNA-dependent protein kinase
DSB double strand break
EGFP Enhanced Green Fluorescent Protein
ESCC esophageal squamous cell cancer
EXO1 exonuclease 1
FBS fetal bovine serum
GANIL “Grand Accélérateur National d’Ions Lourds”
GSI GSI Helmholtzzentrum für Schwerionenforschung GmbH
HEK human embryonic kidney
HIMAC Heavy Ion Medical Accelerator in Chiba
HR Homologous Recombination
HSPC hematopoietic stem and progenitor cells
IAP inhibitor of apoptosis protein
IκBα inhibitor of NF-κB α
IKK IκB kinase
IκBα-SR super-repressor variant of IκBα
ISS International Space Station
k.d. knock-down
LARIA “Laboratoire d’Accueil en Radiobiologie avec les Ions Accélérés”
LET linear energy transfer
MDR1 multi-drug resistance
MeV/n Mega electron Volt per nucleon
MnSOD manganese superoxide dismutase
mRNA messenger RNA
NF-κB Nuclear factor κB
NHEJ Non-Homologous Endjoining
NPCs neural progenitor cells
NRE NF-κB response element
NSCs neural stem cells
P probability
PBL peripheral blood lymphocytes
PBS phosphate buffered saline
PI3K phosphatidyl inositol kinase 3
RBE relative biologic effectiveness
Rel Reticuloendotheliosis
RT-qPCR Reverse Transcriptase real-time quantitative PCR
shRNA RelA RelA short-hairpin RNA
SD standard deviation
SE standard error
TK thymidine kinase
TLR5 Toll-like receptor 5
TNF-α tumor necrosis factor α
TP53 tumor protein p53
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Appendix
Table A1. Gene list of QPCR Array PAHS-225ZD.
UniGene GeneBank Symbol Description Gene Names
Hs.441047 NM_001124 ADM Adrenomedullin AM
Hs.19383 NM_000029 AGT Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) ANHU, FLJ92595, FLJ97926, SERPINA8
Hs.525622 NM_005163 AKT1 V-akt murine thymoma viral oncogene homolog 1 AKT, MGC99656, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA
Hs.499886 NM_000382 ALDH3A2 Aldehyde dehydrogenase 3 family, member A2 ALDH10, DKFZp686E23276, FALDH, FLJ20851, SLS
Hs.227817 NM_004049 BCL2A1 BCL2-related protein A1 ACC-1, ACC-2, BCL2L5, BFL1, GRS, HBPA1
Hs.516966 NM_138578 BCL2L1 BCL2-like 1 BCL-XL, S, BCL2L, BCLX, BCLXL, BCLXS, Bcl-X, DKFZp781P2092,bcl-xL, bcl-xS
Hs.696238 NM_001166 BIRC2 Baculoviral IAP repeat containing 2 API1, HIAP2, Hiap-2, MIHB, RNF48, c-IAP1, cIAP1
Hs.127799 NM_001165 BIRC3 Baculoviral IAP repeat containing 3 AIP1, API2, CIAP2, HAIP1, HIAP1, MALT2, MIHC, RNF49, c-IAP2
Hs.529053 NM_000064 C3 Complement component 3 AHUS5, ARMD9, ASP, CPAMD1
Hs.54460 NM_002986 CCL11 Chemokine (C-C motif) ligand 11 MGC22554, SCYA11
Hs.303649 NM_002982 CCL2 Chemokine (C-C motif) ligand 2 GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1, MGC9434,SCYA2, SMC-CF
Hs.534347 NM_002990 CCL22 Chemokine (C-C motif) ligand 22 ABCD-1, DC, B-CK, MDC, MGC34554, SCYA22, STCP-1
Hs.514821 NM_002985 CCL5 Chemokine (C-C motif) ligand 5 D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228
Hs.523852 NM_053056 CCND1 Cyclin D1 BCL1, D11S287E, PRAD1, U21B31
Hs.450802 NM_000579 CCR5 Chemokine (C-C motif) receptor 5 CC-CKR-5, CCCKR5, CD195, CKR-5, CKR5, CMKBR5, FLJ78003,IDDM22
Hs.472860 NM_001250 CD40 CD40 molecule, TNF receptor superfamily member 5 Bp50, CDW40, MGC9013, TNFRSF5, p50
Hs.208854 NM_001781 CD69 CD69 molecule CLEC2C
Hs.838 NM_005191 CD80 CD80 molecule B7, B7-1, B7.1, BB1, CD28LG, CD28LG1, LAB7
Hs.595133 NM_004233 CD83 CD83 molecule BL11, HB15
Hs.370771 NM_000389 CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) CAP20, CDKN1, CIP1, MDA-6, P21, SDI1, WAF1, p21CIP1
Hs.69771 NM_001710 CFB Complement factor B AHUS4, BF, BFD, CFAB, FB, FBI12, FLJ54899, GBG, H2-Bf, PBF2
Hs.591402 NM_000757 CSF1 Colony stimulating factor 1 (macrophage) MCSF, MGC31930
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UniGene GeneBank Symbol Description Gene Names
Hs.1349 NM_000758 CSF2 Colony stimulating factor 2 (granulocyte-macrophage) GMCSF, MGC131935, MGC138897
Hs.592192 NM_000395 CSF2RB Colony stimulating factor 2 receptor, beta, low-affinity(granulocyte-macrophage) CD131, CDw131, IL3RB, IL5RB
Hs.2233 NM_000759 CSF3 Colony stimulating factor 3 (granulocyte) C17orf33, CSF3OS, GCSF, MGC45931
Hs.789 NM_001511 CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growthstimulating activity, alpha) FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1
Hs.632586 NM_001565 CXCL10 Chemokine (C-X-C motif) ligand 10 C7, IFI10, INP10, IP-10, SCYB10, crg-2, gIP-10, mob-1
Hs.590921 NM_002089 CXCL2 Chemokine (C-X-C motif) ligand 2 CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2, MIP2A, SCYB2
Hs.77367 NM_002416 CXCL9 Chemokine (C-X-C motif) ligand 9 CMK, Humig, MIG, SCYB9, crg-10
Hs.488293 NM_005228 EGFR Epidermal growth factor receptor ERBB, ERBB1, HER1, PIG61, mENA
Hs.1395 NM_000399 EGR2 Early growth response 2 AT591, CMT1D, CMT4E, DKFZp686J1957, FLJ14547, KROX20
Hs.62192 NM_001993 F3 Coagulation factor III (thromboplastin, tissue factor) CD142, FLJ17960, TF, TFA
Hs.654450 NM_000132 F8 Coagulation factor VIII, procoagulant component AHF, DXS1253E, F8B, F8C, FVIII, HEMA
Hs.244139 NM_000043 FAS Fas (TNF receptor superfamily, member 6) ALPS1A, APO-1, APT1, CD95, FAS1, FASTM, TNFRSF6
Hs.2007 NM_000639 FASLG Fas ligand (TNF superfamily, member 6) APT1LG1, CD178, CD95-L, CD95L, FASL, TNFSF6
Hs.110571 NM_015675 GADD45B Growth arrest and DNA-damage-inducible, beta DKFZp566B133, GADD45BETA, MYD118
Hs.643447 NM_000201 ICAM1 Intercellular adhesion molecule 1 BB2, CD54, P3.58
Hs.93177 NM_002176 IFNB1 Interferon, beta 1, fibroblast IFB, IFF, IFNB, MGC96956
Hs.856 NM_000619 IFNG Interferon, gamma IFG, IFI
Hs.674 NM_002187 IL12B Interleukin 12B (natural killer cell stimulatory factor 2, cytotoxiclymphocyte maturation factor 2, p40) CLMF, CLMF2, IL-12B, NKSF, NKSF2
Hs.654378 NM_000585 IL15 Interleukin 15 IL-15, MGC9721
Hs.1722 NM_000575 IL1A Interleukin 1, alpha IL-1A, IL1, IL1-ALPHA, IL1F1
Hs.126256 NM_000576 IL1B Interleukin 1, beta IL-1, IL1-BETA, IL1F2
Hs.25333 NM_004633 IL1R2 Interleukin 1 receptor, type II CD121b, IL1RB, MGC47725
Hs.81134 NM_000577 IL1RN Interleukin 1 receptor antagonist DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3, IL1F3, IL1RA, IRAP,MGC10430, MVCD4
Hs.89679 NM_000586 IL2 Interleukin 2 IL-2, TCGF, lymphokine
Hs.231367 NM_000417 IL2RA Interleukin 2 receptor, alpha CD25, IDDM10, IL2R, TCGFR
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UniGene GeneBank Symbol Description Gene Names
Hs.73917 NM_000589 IL4 Interleukin 4 BCGF-1, BCGF1, BSF-1, BSF1, IL-4, MGC79402
Hs.654458 NM_000600 IL6 Interleukin 6 (interferon, beta 2) BSF2, HGF, HSF, IFNB2, IL-6
Hs.624 NM_000584 IL8 Interleukin 8 CXCL8, GCP-1, GCP1, LECT, LUCT, LYNAP, MDNCF, MONAP,NAF, NAP-1, NAP1
Hs.654579 NM_000207 INS Insulin IDDM2, ILPR, IRDN, MODY10
Hs.436061 NM_002198 IRF1 Interferon regulatory factor 1 IRF-1, MAR
Hs.36 NM_000595 LTA Lymphotoxin alpha (TNF superfamily, member 1) LT, TNFB, TNFSF1
Hs.376208 NM_002341 LTB Lymphotoxin beta (TNF superfamily, member 3) TNFC, TNFSF3, p33
Hs.463978 NM_002758 MAP2K6 Mitogen-activated protein kinase kinase 6 MAPKK6, MEK6, MKK6, PRKMK6, SAPKK3
Hs.297413 NM_004994 MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDatype IV collagenase) CLG4B, GELB, MANDP2, MMP-9
Hs.202453 NM_002467 MYC V-myc myelocytomatosis viral oncogene homolog (avian) MRTL, bHLHe39, c-Myc
Hs.82116 NM_002468 MYD88 Myeloid differentiation primary response gene (88) MYD88D
Hs.592142 NM_181659 NCOA3 Nuclear receptor coactivator 3 ACTR, AIB-1, AIB1, CAGH16, CTG26, KAT13B, MGC141848,RAC3, SRC-3, SRC3, TNRC14, TNRC16, TRAM-1, bHLHe42, pCIP
Hs.654408 NM_003998 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer inB-cells 1
DKFZp686C01211, EBP-1, KBF1, MGC54151, NF-kappa-B,
NF-kappaB, NFKB-p105, NFKB-p50, NFkappaB, p105, p50
Hs.73090 NM_002502 NFKB2 Nuclear factor of kappa light polypeptide gene enhancer inB-cells 2 (p49/p100) LYT-10, LYT10, p52
Hs.81328 NM_020529 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer inB-cells inhibitor, alpha IKBA, MAD-3, NFKBI
Hs.406515 NM_000903 NQO1 NAD(P)H dehydrogenase, quinone 1 DHQU, DIA4, DTD, NMOR1, NMORI, QR1
Hs.563344 NM_006186 NR4A2 Nuclear receptor subfamily 4, group A, member 2 HZF-3, NOT, NURR1, RNR1, TINUR
Hs.1976 NM_002608 PDGFB Platelet-derived growth factor beta polypeptide FLJ12858, PDGF2, SIS, SSV, c-sis
Hs.77274 NM_002658 PLAU Plasminogen activator, urokinase ATF, UPA, URK, u-PA
Hs.196384 NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/Hsynthase and cyclooxygenase) COX-2, COX2, GRIPGHS, PGG, HS, PGHS-2, PHS-2, hCox-2
Hs.631886 NM_002908 REL V-rel reticuloendotheliosis viral oncogene homolog (avian) C-Rel
Hs.502875 NM_021975 RELA V-rel reticuloendotheliosis viral oncogene homolog A (avian) MGC131774, NFKB3, p65
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UniGene GeneBank Symbol Description Gene Names
Hs.642990 NM_007315 STAT1 Signal transducer and activator of transcription 1, 91kDa DKFZp686B04100, ISGF-3, STAT91
Hs.654402 NM_006509 RELB V-rel reticuloendotheliosis viral oncogene homolog B I-REL, IREL, REL-B
Hs.89546 NM_000450 SELE Selectin E CD62E, ELAM, ELAM1, ESEL, LECAM2
Hs.73800 NM_003005 SELP Selectin P (granule membrane protein 140kDa, antigen CD62) CD62, CD62P, FLJ45155, GMP140, GRMP, LECAM3, PADGEM,PSEL
Hs.167317 NM_003081 SNAP25 Synaptosomal-associated protein, 25kDa FLJ23079, RIC-4, RIC4, SEC9, SNAP, SNAP-25, bA416N4.2,dJ1068F16.2
Hs.487046 NM_000636 SOD2 Superoxide dismutase 2, mitochondrial IPOB, MNSOD, MVCD6
Hs.463059 NM_003150 STAT3 Signal transducer and activator of transcription 3 (acute-phaseresponse factor) APRF, FLJ20882, HIES, MGC16063
Hs.595276 NM_012448 STAT5B Signal transducer and activator of transcription 5B STAT5
Hs.241570 NM_000594 TNF Tumor necrosis factor DIF, TNF-alpha, TNFA, TNFSF2
Hs.256278 NM_001066 TNFRSF1B Tumor necrosis factor receptor superfamily, member 1B CD120b, TBPII, TNF-R-II, TNF-R75, TNFBR, TNFR1B, TNFR2,TNFR80, p75, p75TNFR
Hs.478275 NM_003810 TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 APO2L, Apo-2L, CD253, TL2, TRAIL
Hs.654481 NM_000546 TP53 Tumor protein p53 FLJ92943, LFS1, P53, TRP53
Hs.522506 NM_021138 TRAF2 TNF receptor-associated factor 2 MGC:45012, TRAP, TRAP3
Hs.109225 NM_001078 VCAM1 Vascular cell adhesion molecule 1 CD106, DKFZp779G2333, INCAM-100, MGC99561
Hs.356076 NM_001167 XIAP X-linked inhibitor of apoptosis API3, BIRC4, FLJ26913, IAP-3, ILP1, MIHA, XLP2, hIAP-3, hIAP3
Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1
Hs.534255 NM_004048 B2M Beta-2-microglobulin -
Hs.592355 NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase G3PD, GAPD, MGC88685
Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1 HGPRT, HPRT
Hs.546285 NM_001002 RPLP0 Ribosomal protein, large, P0 L10E, LP0, MGC111226, MGC88175, P0, PRLP0, RPP0
N/A SA_00105 HGDC Human Genomic DNA Contamination HIGX1A
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UniGene GeneBank Symbol Description Gene Names
Hs.131431 NM_002759 EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 EIF2AK1/PKR
Hs.141125 NM_004346 CASP3 Caspase 3, apoptosis-related cysteine peptidase CPP32/CPP32B
Hs.146806 NM_003592 CUL1 Cullin 1 MGC149834
Hs.147433 NM_182649 PCNA Proliferating cell nuclear antigen MGC8367
Hs.160953 NM_022112 P53AIP1 P53-regulated apoptosis-inducing protein 1 P53AIP1
Hs.1770 NM_000234 LIG1 Ligase I, DNA, ATP-dependent MGC117397
Hs.191334 NM_003362 UNG Uracil-DNA glycosylase DGU/DKFZp781L1143
Hs.191356 NM_001515 GTF2H2 General transcription factor IIH, polypeptide 2, 44 kDa BTF2/BTF2P44
Hs.193717 NM_000572 IL10 Interleukin 10 CSIF/IL-10
Hs.194143 NM_007294 BRCA1 Breast cancer 1, early onset BRCAI/BRCC1
Hs.2420 NM_003102 SOD3 Superoxide dismutase 3, extracellular EC-SOD
Hs.244723 NM_001238 CCNE1 Cyclin E1 CCNE
Hs.24529 NM_001274 CHEK1 CHK1 checkpoint homolog (S. pombe) CHK1
Hs.271791 NM_001184 ATR Ataxia telangiectasia and Rad3 related FRP1/MEC1
Hs.290758 NM_001923 DDB1 Damage-specific DNA binding protein 1, 127 kDa DDBA/UV-DDB1
Hs.291363 NM_007194 CHEK2 CHK2 checkpoint homolog (S. pombe) CDS1/CHK2
Hs.31210 NM_005178 BCL3 B-cell CLL/lymphoma 3 BCL4/D19S37
Hs.321045 NM_014002 IKBKE Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon IKK-i/IKKE
Hs.326035 NM_001964 EGR1 Early growth response 1 AT225/G0S30
Hs.329502 NM_001229 CASP9 Caspase 9, apoptosis-related cysteine peptidase APAF-3/APAF3
Hs.334562 NM_001786 CDC2 Cell division cycle 2, G1 to S and G2 to M CDC28A/CDK1
Hs.34012 NM_000059 BRCA2 Breast cancer 2, early onset BRCC2/FACD
Hs.367437 NM_000051 ATM Ataxia telangiectasia mutated AT1/ATA
Hs.380271 NM_002542 OGG1 8-oxoguanine DNA glycosylase HMMH/HOGG1
Hs.388739 NM_021141 XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-breakrejoining; Ku autoantigen, 80 kDa) KARP-1/KARP1
Hs.408528 NM_000321 RB1 Retinoblastoma 1 (including osteosarcoma) OSRC/RB
Hs.431850 NM_002745 MAPK1 Mitogen-activated protein kinase 1 ERK/ERK2
Hs.43505 NM_003639 IKBKG Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma AMCBX1/FIP-3
Hs.437705 NM_001789 CDC25A Cell division cycle 25 homolog A (S. pombe) CDC25A2
Hs.443914 NM_000454 SOD1 Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) ALS/ALS1
Hs.445203 NM_001539 DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 DJ-2/DjA1
Hs.460996 NM_003789 TRADD TNFRSF1A-associated via death domain Hs.89862
Hs.469872 NM_000122 ERCC3 Excision repair cross-complementing rodent repair deficiency, complementation group 3(xeroderma pigmentosum group B complementing) BTF2/GTF2H
Hs.492208 NM_002485 NBN Nibrin AT-V1/AT-V2
Hs.498248 NM_130398 EXO1 Exonuclease 1 HEX1/hExoI
Hs.502302 NM_001752 CAT Catalase MGC138422
Hs.505033 NM_004985 KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog C-K-RAS/K-RAS2A
Hs.505777 NM_004083 DDIT3 DNA-damage-inducible transcript 3 CEBPZ/CHOP
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Hs.512599 NM_000077 CDKN2A Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) ARF/CDK4I
Hs.514527 NM_001168 BIRC5 Baculoviral IAP repeat-containing 5 (survivin) API4/EPR-1
Hs.520028 NM_005345 HSPA1A Heat shock 70 kDa protein 1A HSP70-1/HSP72
Hs.523185 NM_012423 RPL13A Ribosomal protein L13a RPL13A
Hs.523560 NM_001040141 HSP90AA2 Heat shock protein 90 kDa alpha (cytosolic), class A member 2 HSP90ALPHA/HSPCA
Hs.523968 NM_005426 TP53BP2 Tumor protein p53 binding protein, 2 53BP2/ASPP2
Hs.525704 NM_002228 JUN Jun oncogene AP1/c-Jun
Hs.530227 NM_005526 HSF1 Heat shock transcription factor 1 HSTF1
Hs.531704 NM_002737 PRKCA Protein kinase C, alpha AAG6/PKC-alpha
Hs.544577 NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase G3PD/GAPD
Hs.553498 NM_006218 PIK3CA Phosphoinositide-3-kinase, catalytic, alpha polypeptide PI3K/p110-alpha
Hs.567303 NM_002392 MDM2 Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) HDMX/hdm2
Hs.567387 NM_057749 CCNE2 Cyclin E2 CYCE2
Hs.591084 NM_004629 FANCG Fanconi anemia, complementation group G FAG/XRCC9
Hs.591980 NM_000378 WT1 Wilms tumor 1 GUD/WAGR
Hs.592325 NM_005432 XRCC3 X-ray repair complementing defective repair in Chinese hamster cells 3 XRCC3
Hs.592839 NM_005633 SOS1 Son of sevenless homolog 1 (Drosophila) GF1/GGF1
Hs.61188 NM_033276 XRCC6BP1 XRCC6 binding protein 1 KUB3
Hs.631709 NM_002875 RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) BRCC5/HRAD51
Hs.647093 NM_005431 XRCC2 X-ray repair complementing defective repair in Chinese hamster cells 2 DKFZp781P0919
Hs.647371 NM_005953 MT2A Metallothionein 2A MT2
Hs.654393 NM_005225 E2F1 E2F transcription factor 1 E2F-1/RBBP3
Hs.654532 NM_003263 TLR1 Toll-like receptor 1 CD281/DKFZp547I0610
Hs.655354 NM_004584 RAD9A RAD9 homolog A (S. pombe) RAD9
Hs.655983 NM_001228 CASP8 Caspase 8, apoptosis-related cysteine peptidase ALPS2B/CAP4
Hs.656458 NM_001556 IKBKB Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta IKK-beta/IKK2
Hs.695926 NM_002890 RASA1 RAS p21 protein activator (GTPase activating protein) 1 CM-AVM/CMAVM
Hs.697294 NM_005427 TP73 Tumor protein p73 P73
Hs.706746 NM_000625 NOS2A Nitric oxide synthase 2A (inducible, hepatocytes) HEP-NOS/INOS
Hs.708288 NM_000165 GJA1 Gap junction protein, alpha 1, 43 kDa CX43/DFNB38
Hs.73133 NM_005954 MT3 Metallothionein 3 GIF/GIFB
Hs.76686 NM_000581 GPX1 Glutathione peroxidase 1 GSHPX1
Hs.80409 NM_001924 GADD45A Growth arrest and DNA-damage-inducible, alpha DDIT1/GADD45
Hs.87247 NM_003806 HRK Harakiri, BCL2 interacting protein (contains only BH3 domain) DP5/HARAKIRI
Hs.9701 NM_006705 GADD45G Growth arrest and DNA-damage-inducible, gamma CR6/DDIT2
Hs.98493 NM_006297 XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 RCC
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Table A3. Basal gene expression in HEK shRNA RelA cells compared to the original cell line
HEK-pNF-κB-d2EGFP/Neo L2 using the RT2 Profiler PCR array.
Symbol µ SE Symbol µ SE Symbol µ SE
ACTB 1.02 0.06 CFB −1.12 0.13 HSP90AA2 1.74 0.19
ADM 1.42 0.23 CHEK1 1.01 0.16 HSPA1A 1.86 0.33
AGT −1.02 0.13 CHEK2 −1.11 0.06 ICAM1 1.13 0.16
AKT1 −1.11 0.10 CSF1 −1.24 0.06 IFNB1 −1.00 0.05
ALDH3A2 −1.15 0.03 CSF2 1.06 0.18 IFNG −1.00 0.05
ATM −1.79 0.02 CSF2RB −1.00 0.05 IKBKB −1.37 0.06
ATR 1.40 0.08 CSF3 1.35 0.20 IKBKE −2.40 0.02
B2M −1.03 0.07 CUL1 1.04 0.12 IKBKG 1.10 0.27
BCL2A1 1.06 0.11 CXCL1 −1.59 0.12 IL10 1.67 0.43
BCL2L1 1.08 0.13 CXCL10 −1.32 0.15 IL12B −1.15 0.06
BCL3 −1.15 0.21 CXCL2 1.11 0.24 IL15 −1.36 0.11
BIRC2 −1.03 0.09 CXCL9 1.57 0.38 IL1A 1.12 0.17
BIRC3 1.23 0.30 DDB1 1.21 0.28 IL1B 1.09 0.08
BIRC5 1.06 0.10 DDIT3 1.62 0.51 IL1R2 −1.05 0.24
BRCA2 1.08 0.12 DNAJA1 −1.23 0.09 IL1RN −1.00 0.05
BRCA5 −1.04 0.28 E2F1 1.27 0.40 IL2 −1.00 0.05
C3 1.88 0.69 EGFR −1.04 0.11 IL2RA −1.00 0.05
CASP3 1.27 0.09 EGR1 2.15 0.30 IL4 1.97 0.33
CASP8 −1.22 0.30 EGR2 1.30 0.30 IL6 1.27 0.28
CASP9 −1.07 0.06 EIF2AK2 −1.24 0.04 IL8 −2.31 0.13
CAT 1.03 0.22 ERCC3 −1.18 0.09 INS −1.00 0.05
CCL11 1.22 0.32 EXO1 −1.19 0.21 IRF1 −1.11 0.08
CCL2 1.36 0.11 F3 1.20 0.15 JUN 4.96 1.85
CCL22 −1.00 0.05 F8 1.16 0.06 KRAS −1.08 0.02
CCL5 15.57 8.77 FANCG −1.48 0.04 LIG1 −1.18 0.23
CCND1 −2.99 0.05 FAS −1.30 0.13 LTA 1.54 0.33
CCNE1 1.03 0.08 FASLG 2.50 0.54 LTB 1.09 0.25
CCNE2 1.18 0.23 GADD45A −1.27 0.06 MAP2K6 −1.23 0.13
CCR5 1.53 0.28 GADD45B 3.63 1.08 MAPK1 −1.10 0.12
CD40 −1.02 0.15 GADD45G −1.17 0.19 MDM2 −1.24 0.11
CD69 −1.00 0.05 GAPDH 1.13 0.07 MMP9 −1.03 0.23
CD80 1.18 0.26 GJA1 −1.22 0.16 MT2A 1.01 0.07
CD83 −1.50 0.09 GPX1 1.52 0.17 MT3 1.88 0.80
CDC2 1.12 0.21 GTF2H2 −1.24 0.06 MYC 1.14 0.20
CDC25A 1.22 0.10 HPRT1 1.21 0.08 MYD88 −1.33 0.17
CDKN1A 1.37 0.31 HRK 1.12 0.48 NBN −2.37 0.09
CDKN2A 1.11 0.06 HSF1 1.06 0.21 NCOA3 1.33 0.06
NFKB1 1.00 0.06 RB1 1.00 0.04 TNF −1.69 0.12
NFKB2 1.19 0.16 REL −1.27 0.04 TNFRSF1B 1.02 0.25
NFKBIA −1.64 0.08 RELA −4.93 0.02 TNFSF10 −1.01 0.23
NOS2 1.40 0.32 RELB 1.14 0.22 TP53 −1.17 0.04
NQO1 1.28 0.19 RPL13A −1.12 0.13 TP53BP2 −1.13 0.10
NR4A2 2.40 0.23 RPLP0 −1.19 0.06 TP73 1.02 0.09
OGG1 1.02 0.18 SELE 1.64 0.38 TRADD −1.46 0.04
P53AIP1 1.45 0.30 SELP −1.00 0.05 TRAF2 −1.12 0.03
PCNA 1.28 0.16 SNAP25 1.79 0.38 UNG 1.66 0.18
PDGFB −1.00 0.05 SOD1 1.21 0.15 VCAM1 −1.00 0.05
PIK3Ca 1.13 0.07 SOD2 −1.09 0.06 WT1 1.25 0.19
PLAU −1.52 0.14 SOD3 2.03 0.75 XIAP −1.10 0.12
PRKCA −1.03 0.12 SOS1 −1.11 0.13 XRCC1 1.01 0.09
PTGS2 1.96 0.38 STAT1 1.25 0.05 XRCC2 −1.52 0.07
RAD51 1.02 0.05 STAT3 −1.10 0.04 XRCC3 1.04 0.31
RAD9A 1.04 0.04 STAT5B −1.08 0.09 XRCC5 1.10 0.11
RASA1 −1.24 0.05 TLR1 1.15 0.03 XRCC6BP1 −1.20 0.10
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Table A4. TNF-α induced gene expression in HEK shRNA RelA cells (RelA k.d.) compared to the
original cell line HEK-pNF-κB-d2EGFP/Neo L2 (HEK wt) using the RT2 Profiler PCR array.
HEK wt RelA k.d.
Symbol µ SE µ SE
ACTB −1.19 0.05 −1.26 0.07
ADM −1.88 0.08 1.39 0.27
AGT 1.57 0.42 −1.06 0.11
AKT1 −1.36 0.08 1.04 0.16
ALDH3A2 −1.19 0.02 −1.23 0.03
ATM −1.01 0.03 1.19 0.06
ATR −1.50 0.05 1.35 0.03
B2M 1.58 0.14 1.27 0.07
BCL2A1 2.22 0.32 1.47 0.20
BCL2L1 1.65 0.19 1.17 0.08
BCL3 2.38 0.44 1.67 0.47
BIRC2 1.54 0.13 1.27 0.12
BIRC3 4.76 0.98 2.03 0.47
BIRC5 −1.36 0.10 −1.09 0.01
BRCA2 1.21 0.07 1.48 0.22
BRCA5 2.04 0.67 1.47 0.33
C3 5.97 1.39 1.97 0.57
CASP3 −1.04 0.10 1.44 0.02
CASP8 1.97 0.74 1.80 0.56
CASP9 1.08 0.07 −1.02 0.05
CAT −1.44 0.18 −1.18 0.11
CCL11 3.73 1.51 1.84 0.57
CCL2 3.04 0.24 −1.28 0.09
CCL22 1.39 0.24 −1.15 0.04
CCL5 4.79 1.79 29.02 12.66
CCND1 −2.35 0.11 −1.55 0.09
CCNE1 −1.13 0.09 −1.10 0.04
CCNE2 1.40 0.33 1.56 0.22
CCR5 1.61 0.49 −2.87 0.06
CD40 2.83 0.53 1.51 0.30
CD69 3.37 0.23 −1.15 0.04
CD80 2.06 0.50 2.32 0.77
CD83 5.68 0.82 1.67 0.08
CDC2 1.16 0.16 1.38 0.31
CDC25A 1.25 0.02 −1.04 0.11
CDKN1A 2.85 0.50 2.59 0.59
CDKN2A −1.35 0.04 −1.14 0.04
CFB 2.21 0.36 1.36 0.17
CHEK1 1.35 0.25 1.15 0.15
CHEK2 1.18 0.06 1.14 0.09
CSF1 2.55 0.25 −1.14 0.02
CSF2 1.16 0.37 −1.32 0.10
CSF2RB −1.07 0.05 −1.15 0.04
CSF3 1.07 0.30 1.13 0.21
CUL1 1.08 0.15 −1.09 0.06
CXCL1 47.46 11.75 −1.05 0.08
CXCL10 23.38 5.72 −1.18 0.06
CXCL2 18.29 3.92 1.72 0.33
CXCL9 2.08 0.62 1.72 0.45
DDB1 −1.10 0.27 −1.33 0.10
DDIT3 1.88 0.63 1.91 0.50
DNAJA1 1.48 0.24 1.07 0.02
E2F1 −1.31 0.28 −1.28 0.18
EGFR 1.80 0.20 1.33 0.14
EGR1 −1.06 0.18 1.23 0.03
EGR2 1.98 0.57 1.81 0.47
EIF2AK2 1.06 0.06 1.09 0.04
ERCC3 1.26 0.01 1.12 0.17
EXO1 1.97 0.67 −4.29 0.02
F3 2.66 0.30 1.66 0.22
F8 −1.23 0.10 1.26 0.02
FANCG 1.26 0.08 1.18 0.05
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Table A4. Cont.
HEK wt RelA k.d.
Symbol µ SE µ SE
FAS −1.39 0.13 −1.13 0.16
FASLG 1.28 0.47 −1.01 0.18
GADD45A 1.38 0.15 1.86 0.00
GADD45B 2.01 0.56 2.60 0.91
GADD45G −1.01 0.24 1.12 0.20
GAPDH −1.29 0.06 −1.32 0.04
GJA1 −1.03 0.12 −1.46 0.17
GPX1 −1.17 0.13 −1.34 0.03
GTF2H2 1.42 0.02 1.24 0.13
HPRT1 −1.13 0.07 1.40 0.17
HRK 2.12 0.76 2.45 1.08
HSF1 1.60 0.44 −1.00 0.07
HSP90AA2 1.17 0.16 1.05 0.07
HSPA1A −1.51 0.15 −1.04 0.08
ICAM1 2.12 0.36 −2.56 0.05
IFNB1 −1.01 0.05 −1.15 0.04
IFNG −1.36 0.17 −1.15 0.04
IKBKB 1.20 0.14 1.05 0.00
IKBKE 1.22 0.08 −1.83 0.03
IKBKG 1.01 0.33 −1.75 0.06
IL10 1.41 0.26 −1.80 0.17
IL12B 1.82 0.32 1.42 0.07
IL15 2.83 0.63 1.59 0.07
IL1A 1.59 0.19 1.38 0.23
IL1B −1.10 0.07 1.27 0.12
IL1R2 4.02 1.29 1.71 0.30
IL1RN 1.39 0.24 −1.15 0.04
IL2 −1.27 0.13 −1.15 0.04
IL2RA 1.35 0.21 −1.15 0.04
IL4 1.62 0.43 −1.12 0.14
IL6 1.01 0.23 1.05 0.18
IL6 1.86 0.58 2.39 0.50
IL8 17.83 5.19 −1.15 0.04
INS −1.27 0.12 1.29 0.11
IRF1 3.16 0.40 −1.18 0.12
JUN 1.39 0.69 1.15 0.01
KRAS 1.11 0.02 −1.42 0.10
LIG1 −1.24 0.29 1.58 0.38
LTA 1.52 0.51 2.06 0.67
LTB 1.92 0.58 −1.80 0.13
MAP2K6 −1.57 0.12 −1.08 0.11
MAPK1 −1.13 0.13 1.02 0.13
MDM2 −1.01 0.13 2.01 0.37
MMP9 3.34 0.61 −1.53 0.06
MT2A −1.13 0.02 −1.04 0.45
MT3 1.86 0.58 −1.10 0.16
MYC −1.84 0.08 2.09 0.70
MYD88 1.49 0.35 1.01 0.29
NBN −1.18 0.06 1.12 0.08
NCOA3 −1.02 0.06 1.22 0.04
NFKB1 2.88 0.28 1.47 0.13
NFKB2 2.90 0.61 1.79 0.40
NFKBIA 11.88 1.66 2.52 0.30
NOS2 1.91 0.52 1.32 0.20
NQO1 −1.76 0.10 −1.10 0.05
NR4A2 1.17 0.18 1.22 0.21
OGG1 −1.19 0.10 −1.19 0.19
P53AIP1 1.64 0.09 1.42 0.41
PCNA 1.36 0.14 1.25 0.18
PDGFB 1.17 0.12 −1.15 0.04
PIK3Ca 1.20 0.08 1.19 0.06
PLAU 3.35 0.57 2.64 0.58
PRKCA −1.00 0.17 −1.21 0.05
PTGS2 3.99 0.53 2.17 0.39
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Table A4. Cont.
HEK wt RelA k.d.
Symbol µ SE µ SE
RAD51 −1.00 0.02 1.00 0.07
RAD9A 1.10 0.02 −1.31 0.04
RASA1 1.11 0.07 1.27 0.07
RB1 1.07 0.03 1.08 0.05
REL 2.40 0.25 1.33 0.07
RELA 1.69 0.17 −1.11 0.06
RELB 1.82 0.55 1.21 0.23
RPL13A −1.29 0.09 −1.12 0.15
RPLP0 1.46 0.12 1.10 0.05
SELE 1.86 0.71 1.06 0.19
SELP 1.17 0.11 −1.15 0.04
SNAP25 1.48 0.31 2.06 0.64
SOD1 −1.28 0.13 −1.16 0.05
SOD2 −1.17 0.09 −1.10 0.06
SOD3 1.86 0.58 −1.42 0.27
SOS1 1.25 0.19 1.08 0.14
STAT1 1.07 0.11 1.01 0.04
STAT3 −1.15 0.09 1.02 0.06
STAT5B 1.35 0.18 1.28 0.17
TLR1 −1.40 0.01 −2.09 0.02
TNF 60.95 12.42 3.40 0.54
TNFRSF1B 1.49 0.34 4.13 2.29
TNFSF10 1.73 0.37 2.07 0.78
TP53 1.17 0.05 1.16 0.06
TP53BP2 1.31 0.17 −1.00 0.09
TP73 1.11 0.12 −2.03 0.04
TRADD 1.09 0.06 −1.42 0.04
TRAF2 1.23 0.11 1.04 0.05
UNG −1.23 0.12 −1.09 0.05
VCAM1 −1.36 0.15 −1.15 0.04
WT1 1.20 0.01 −1.64 0.13
XIAP 1.50 0.21 1.37 0.17
XRCC1 1.04 0.13 −1.17 0.02
XRCC2 1.17 0.14 1.42 0.11
XRCC3 −1.28 0.27 −1.65 0.13
XRCC5 −1.17 0.12 1.05 0.01
XRCC6BP1 −1.08 0.02 −1.09 0.15
Table A5. Relative gene expression in HEK-pNF-κB-d2EGFP/Neo L2 (HEK wt) and HEK shRNA RelA
(RelA k.d.) cells after irradiation using the RT2 Profiler PCR array: X-rays.
HEK wt RelA k.d.
0.5 Gy 4 Gy 8 Gy 0.5 Gy 4 Gy 8 Gy
Symbol µ SE µ SE µ SE µ SE µ SE µ SE
ADM −1.09 0.11 −1.04 0.09 −1.16 0.08 1.02 0.20 1.18 0.23 1.15 0.22
AGT −1.35 0.23 1.80 0.57 1.56 0.47 1.07 0.12 1.17 0.13 −1.00 0.11
AKT1 1.08 0.06 1.05 0.05 1.12 0.05 1.22 0.19 1.31 0.20 1.29 0.20
ALDH3A2 1.16 0.04 1.01 0.07 −1.08 0.06 1.06 0.04 −1.03 0.04 −1.01 0.04
BCL2A1 1.15 0.19 1.31 0.15 −1.15 0.12 −1.02 0.13 1.45 0.19 1.04 0.14
BCL2L1 1.01 0.11 −1.18 0.09 −1.12 0.13 −1.41 0.05 1.21 0.09 −1.24 0.06
BIRC2 −1.17 0.06 −1.14 0.04 1.02 0.07 −1.37 0.07 −1.02 0.09 −1.08 0.08
BIRC3 −1.31 0.11 1.96 0.38 2.53 0.29 −1.86 0.12 −1.02 0.23 −1.22 0.19
C3 1.98 0.32 1.98 0.32 1.05 0.14 −1.72 0.17 1.43 0.42 1.20 0.35
CCL11 1.40 0.57 2.66 0.78 2.63 0.77 1.88 0.58 1.90 0.59 1.23 0.38
CCL2 −1.21 0.08 1.24 0.15 2.25 0.20 1.25 0.15 1.10 0.13 1.04 0.12
CCL22 1.73 0.32 1.14 0.31 1.08 0.24 1.08 0.05 1.17 0.06 1.15 0.05
CCL5 −1.42 0.24 3.68 1.53 3.34 1.40 1.55 0.68 2.07 0.90 −1.47 0.30
CCND1 1.02 0.19 1.15 0.18 1.20 0.18 1.46 0.21 2.16 0.30 2.13 0.30
CCR5 −1.34 0.28 1.78 0.61 1.49 0.44 1.55 0.28 1.52 0.27 −1.01 0.18
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Table A5. Cont.
HEK wt RelA k.d.
0.5 Gy 4 Gy 8 Gy 0.5 Gy 4 Gy 8 Gy
Symbol µ SE µ SE µ SE µ SE µ SE µ SE
CD40 1.09 0.18 1.27 0.15 1.21 0.16 −1.02 0.19 1.42 0.28 −1.14 0.17
CD69 1.28 0.10 1.14 0.11 −1.01 0.08 1.08 0.05 1.17 0.06 1.15 0.05
CD80 −1.63 0.17 1.45 0.35 1.29 0.25 −1.34 0.25 2.42 0.80 −1.35 0.24
CD83 −1.01 0.03 2.47 0.08 3.75 0.18 1.12 0.06 1.67 0.08 2.27 0.11
CDKN1A 1.41 0.19 1.81 0.19 1.84 0.21 1.17 0.33 1.58 0.45 2.04 0.58
CFB 1.21 0.14 −1.09 0.08 −1.20 0.09 −1.33 0.09 −1.39 0.09 −1.15 0.11
CSF1 1.31 0.12 1.52 0.13 1.92 0.14 1.13 0.02 1.28 0.03 1.30 0.03
CSF2 −1.49 0.27 −1.02 0.32 1.30 0.46 1.44 0.19 1.41 0.19 −1.06 0.13
CSF2RB 1.07 0.08 −1.00 0.08 −1.13 0.06 1.08 0.05 1.17 0.06 1.15 0.05
CSF3 −1.55 0.22 1.53 0.54 1.82 0.62 1.26 0.23 1.03 0.19 −1.31 0.14
CXCL1 1.04 0.20 3.57 0.56 6.96 1.01 1.06 0.09 1.52 0.12 2.02 0.16
CXCL10 −1.10 0.16 4.68 0.60 14.58 2.57 1.05 0.08 2.23 0.16 2.04 0.15
CXCL2 −1.35 0.13 2.33 0.33 3.01 0.40 −1.04 0.19 1.55 0.30 1.29 0.25
CXCL9 −2.11 0.17 1.58 0.56 1.75 0.48 −1.43 0.18 1.38 0.36 −1.25 0.21
EGFR 1.25 0.12 1.43 0.11 1.57 0.13 −1.10 0.10 1.04 0.11 −1.07 0.10
EGR2 −1.77 0.19 1.03 0.24 1.32 0.31 −1.65 0.16 1.95 0.51 −1.02 0.26
F3 −1.05 0.11 1.35 0.11 1.56 0.13 1.13 0.15 1.31 0.17 1.67 0.22
F8 −1.39 0.10 −1.36 0.08 −1.45 0.08 −1.35 0.01 −1.55 0.01 −1.48 0.01
FAS 1.35 0.30 1.31 0.21 1.57 0.25 1.68 0.31 1.85 0.34 1.86 0.34
FASLG −1.78 0.25 1.81 0.77 2.39 0.97 1.28 0.23 1.40 0.25 −1.61 0.11
GADD45B −1.83 0.17 1.66 0.49 1.50 0.37 −1.30 0.27 −1.43 0.24 −1.60 0.22
ICAM1 1.46 0.24 1.29 0.17 1.03 0.16 −1.02 0.12 −1.00 0.12 1.11 0.14
IFNB1 1.12 0.07 1.27 0.06 −1.27 0.09 1.08 0.05 1.17 0.06 1.15 0.05
IFNG −1.32 0.22 1.44 0.39 1.41 0.41 1.08 0.05 1.17 0.06 1.15 0.05
IL12B −1.36 0.16 1.45 0.33 1.64 0.31 −1.02 0.05 2.01 0.10 1.13 0.05
IL15 1.14 0.23 2.22 0.58 2.31 0.49 1.08 0.05 1.46 0.06 1.55 0.07
IL1A −1.52 0.11 −1.33 0.11 −1.31 0.09 −1.70 0.12 1.26 0.27 −1.24 0.17
IL1B 1.03 0.09 −1.12 0.10 −1.36 0.09 1.02 0.10 1.10 0.11 1.08 0.10
IL1R2 −1.80 0.16 −1.00 0.24 −1.29 0.18 −1.27 0.14 1.41 0.25 −1.13 0.16
IL1RN 1.73 0.32 1.14 0.31 1.08 0.24 1.08 0.05 1.17 0.06 1.15 0.05
IL2 −1.16 0.18 1.14 0.19 1.03 0.18 1.08 0.05 1.17 0.06 1.15 0.05
IL2RA 1.67 0.28 1.21 0.27 1.30 0.18 1.08 0.05 1.17 0.06 1.15 0.05
IL4 −1.36 0.23 1.51 0.46 1.20 0.33 1.10 0.18 −1.17 0.14 −1.60 0.10
IL6 −1.30 0.22 1.75 0.51 1.53 0.45 1.19 0.12 1.09 0.11 1.07 0.11
IL8 −1.73 0.19 2.42 0.66 3.74 0.86 1.20 0.19 1.38 0.22 1.01 0.16
INS −1.16 0.17 1.22 0.20 1.48 0.34 1.08 0.05 1.17 0.06 1.15 0.05
IRF1 1.27 0.14 1.45 0.15 2.19 0.25 1.08 0.09 1.41 0.12 1.56 0.13
LTA −1.19 0.35 1.77 0.64 1.89 0.60 −1.29 0.19 1.86 0.45 1.00 0.24
LTB −1.87 0.20 1.23 0.38 1.13 0.30 −1.54 0.21 2.67 0.87 1.30 0.42
MAP2K6 −1.20 0.18 −1.91 0.10 −2.78 0.06 −1.15 0.21 −1.09 0.22 −1.02 0.24
MMP9 −1.37 0.04 −1.36 0.03 −1.48 0.03 −1.42 0.13 −1.28 0.14 −1.18 0.16
MYC 1.03 0.05 −1.02 0.06 −1.22 0.04 −1.19 0.15 −1.24 0.14 −1.24 0.14
MYD88 −1.89 0.14 1.24 0.36 1.13 0.27 1.57 0.53 1.60 0.54 1.41 0.47
NCOA3 1.04 0.08 −1.15 0.05 −1.20 0.05 −1.13 0.06 −1.11 0.06 −1.33 0.05
NFKB1 −1.08 0.13 1.62 0.17 2.73 0.30 1.17 0.03 1.21 0.04 1.31 0.04
NFKB2 1.01 0.12 2.93 0.33 4.07 0.45 1.09 0.18 1.48 0.24 1.62 0.26
NFKBIA −1.07 0.08 2.65 0.34 4.26 0.40 −1.13 0.10 1.47 0.17 1.69 0.19
NQO1 1.10 0.12 −1.10 0.12 −1.17 0.10 1.18 0.06 1.21 0.06 1.49 0.08
NR4A2 1.43 0.25 −1.10 0.19 1.03 0.23 −1.02 0.17 1.08 0.19 1.73 0.30
PDGFB 1.41 0.16 1.13 0.17 −1.02 0.14 1.08 0.05 1.17 0.06 1.15 0.05
PLAU −1.11 0.15 2.09 0.49 2.18 0.41 1.22 0.27 1.26 0.28 −1.29 0.17
PTGS2 −1.03 0.03 1.41 0.03 1.77 0.05 −1.62 0.11 −1.21 0.15 −1.35 0.13
REL 1.10 0.15 1.02 0.14 1.40 0.17 −1.32 0.04 −1.07 0.05 −1.07 0.05
RELA 1.10 0.06 1.07 0.04 1.19 0.05 1.00 0.06 1.14 0.07 1.05 0.06
RELB −1.73 0.21 1.68 0.60 1.87 0.51 −1.13 0.17 1.09 0.20 1.02 0.19
SELE −1.79 0.25 1.70 0.68 1.92 0.71 1.36 0.24 1.32 0.24 −1.41 0.13
SELP 1.41 0.15 −1.01 0.21 −1.08 0.15 1.08 0.05 1.17 0.06 1.15 0.05
SNAP25 1.05 0.26 1.21 0.22 1.06 0.19 1.59 0.49 1.86 0.58 1.96 0.61
SOD2 −1.05 0.07 −1.08 0.05 −1.00 0.07 −1.03 0.09 1.02 0.10 1.15 0.11
STAT1 1.15 0.14 −1.17 0.09 −1.10 0.10 −1.08 0.04 −1.14 0.04 −1.25 0.03
STAT3 −1.14 0.10 1.03 0.11 1.12 0.13 −1.13 0.06 −1.15 0.05 −1.16 0.05
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Table A5. Cont.
HEK wt RelA k.d.
0.5 Gy 4 Gy 8 Gy 0.5 Gy 4 Gy 8 Gy
Symbol µ SE µ SE µ SE µ SE µ SE µ SE
STAT5B 1.08 0.16 1.33 0.19 1.24 0.15 1.00 0.13 −1.08 0.12 −1.17 0.11
TNF 1.01 0.11 5.10 0.99 12.90 1.72 1.08 0.05 1.17 0.06 1.15 0.05
TNFRSF1B −1.81 0.16 1.02 0.22 1.11 0.22 −2.15 0.26 4.10 2.28 2.39 1.33
TNFSF10 −1.48 0.17 1.11 0.21 −1.02 0.18 −1.61 0.23 2.81 1.06 1.64 0.62
TP53 1.13 0.02 1.39 0.04 1.67 0.08 −1.14 0.02 −1.02 0.02 −1.04 0.02
TRAF2 1.06 0.11 1.04 0.09 1.12 0.10 1.10 0.05 −1.10 0.04 −1.03 0.04
VCAM1 −1.27 0.20 4.24 1.56 2.94 0.87 1.08 0.05 1.17 0.06 1.15 0.05
XIAP −1.07 0.11 −1.18 0.09 −1.23 0.07 −1.13 0.11 −1.17 0.10 −1.27 0.10
ACTB 1.12 0.10 −1.16 0.08 −1.08 0.07 1.21 0.17 1.08 0.16 −1.04 0.14
B2M −1.05 0.07 1.29 0.14 1.29 0.09 −1.09 0.04 −1.06 0.04 1.08 0.04
GAPDH −1.14 0.04 −1.03 0.04 −1.10 0.05 1.03 0.05 −1.06 0.05 −1.17 0.04
HPRT1 1.04 0.04 1.01 0.03 −1.02 0.04 −1.08 0.12 1.10 0.14 1.21 0.16
RPLP0 1.06 0.05 1.03 0.07 1.01 0.05 1.01 0.05 1.00 0.05 −1.01 0.05
Table A6. Relative gene expression in HEK-pNF-κB-d2EGFP/Neo L2 (HEK wt) and HEK shRNA RelA
(RelA k.d.) cells after irradiation using the RT2 Profiler PCR array: Ti ions.
HEK wt RelA k.d.
0.5 Gy 4 Gy 0.5 Gy 4 Gy
Symbol µ SE µ SE µ SE µ SE
ADM −1.44 0.08 1.14 0.13 1.22 0.24 1.24 0.24
AGT −1.88 0.16 −1.48 0.21 −1.36 0.08 1.11 0.13
AKT1 −1.01 0.05 1.11 0.06 −1.11 0.14 −1.16 0.13
ALDH3A2 −1.05 0.03 −1.16 0.03 1.08 0.04 −1.15 0.04
BCL2A1 −1.21 0.13 1.04 0.17 1.12 0.15 −1.23 0.11
BCL2L1 1.17 0.13 −1.16 0.10 1.36 0.10 −1.68 0.04
BIRC2 1.08 0.07 1.06 0.07 1.26 0.12 −1.17 0.08
BIRC3 1.34 0.20 1.66 0.24 1.29 0.30 −1.16 0.20
C3 1.58 0.25 1.03 0.16 −1.46 0.20 −1.99 0.15
CCL11 1.97 0.81 1.10 0.45 1.46 0.45 1.68 0.52
CCL2 1.18 0.11 2.94 0.27 1.57 0.19 2.64 0.31
CCL22 1.24 0.23 1.57 0.29 −1.26 0.04 −1.12 0.04
CCL5 −1.97 0.17 −1.56 0.22 −1.89 0.23 1.22 0.53
CCND1 −1.77 0.11 1.03 0.19 −1.23 0.11 −1.24 0.11
CCR5 −1.02 0.37 −2.13 0.18 1.04 0.19 1.35 0.24
CD40 1.58 0.26 −1.17 0.14 1.15 0.23 −1.30 0.15
CD69 −1.09 0.07 1.16 0.09 −1.26 0.04 −1.12 0.04
CD80 −1.01 0.27 −1.55 0.18 2.03 0.67 −1.53 0.22
CD83 1.25 0.04 4.37 0.14 1.09 0.05 1.42 0.07
CDKN1A −1.39 0.10 1.21 0.17 −1.35 0.21 −1.07 0.26
CFB 1.01 0.12 1.14 0.14 1.57 0.20 −1.01 0.12
CSF1 −1.15 0.08 1.69 0.15 −1.06 0.02 −1.01 0.02
CSF2 −1.82 0.22 −1.30 0.31 −3.46 0.04 1.48 0.20
CSF2RB −1.30 0.06 −1.03 0.07 −1.26 0.04 −1.12 0.04
CSF3 −1.44 0.24 −1.44 0.24 1.02 0.19 1.46 0.27
CXCL1 1.01 0.19 7.55 1.44 −1.48 0.05 1.21 0.10
CXCL10 −1.27 0.14 6.70 1.20 −1.30 0.06 −1.15 0.06
CXCL2 1.30 0.22 3.48 0.59 1.11 0.21 1.00 0.19
CXCL9 1.02 0.37 −2.17 0.17 1.14 0.30 −1.66 0.16
EGFR −1.33 0.07 −1.12 0.09 −1.05 0.10 −1.08 0.10
EGR2 1.17 0.39 −1.66 0.20 1.57 0.41 −1.52 0.17
F3 −1.15 0.10 1.47 0.17 −1.01 0.13 −1.00 0.13
F8 −1.22 0.12 −1.06 0.13 1.19 0.01 −1.01 0.01
FAS −2.11 0.11 −1.61 0.14 1.14 0.21 1.15 0.21
FASLG −1.40 0.32 −1.51 0.30 −1.10 0.16 1.15 0.21
GADD45B −1.06 0.30 2.19 0.69 1.69 0.59 2.06 0.72
ICAM1 −1.57 0.10 −1.64 0.10 1.14 0.14 1.37 0.17
IFNB1 −1.24 0.05 1.02 0.06 −1.26 0.04 −1.12 0.04
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Table A6. Cont.
HEK wt RelA k.d.
0.5 Gy 4 Gy 0.5 Gy 4 Gy
Symbol µ SE µ SE µ SE µ SE
IFNG −1.84 0.16 −1.46 0.20 −1.26 0.04 −1.12 0.04
IL12B −1.35 0.16 −1.49 0.14 1.25 0.06 1.30 0.06
IL15 −1.32 0.15 1.07 0.22 −1.21 0.04 −1.41 0.03
IL1A −1.39 0.12 −1.83 0.09 1.57 0.33 −1.40 0.15
IL1B −1.35 0.07 −1.07 0.09 −1.02 0.10 −1.18 0.08
IL1R2 −1.29 0.22 −1.99 0.14 1.01 0.18 −1.80 0.10
IL1RN 1.24 0.23 1.57 0.29 −1.26 0.04 −1.12 0.04
IL2 −1.62 0.13 −1.28 0.16 −1.26 0.04 −1.12 0.04
IL2RA 1.20 0.20 1.52 0.25 −1.26 0.04 −1.12 0.04
IL4 −1.12 0.28 −1.17 0.26 −1.26 0.13 1.02 0.16
IL6 −1.81 0.15 −1.43 0.20 −1.27 0.08 1.09 0.11
IL8 1.38 0.44 6.10 1.96 −1.26 0.13 1.44 0.23
INS −1.62 0.12 −1.28 0.15 −1.26 0.04 −1.12 0.04
IRF1 1.06 0.12 2.85 0.33 −1.09 0.08 1.40 0.11
LTA 1.05 0.44 −2.07 0.20 1.28 0.31 −1.39 0.17
LTB 1.16 0.44 −2.18 0.17 1.91 0.62 −1.49 0.22
MAP2K6 −1.17 0.19 −1.63 0.13 1.99 0.48 1.44 0.35
MMP9 1.24 0.07 −1.04 0.06 1.09 0.20 1.07 0.20
MYC −1.14 0.04 1.21 0.05 1.67 0.29 1.97 0.35
MYD88 −1.05 0.24 −1.25 0.21 −1.35 0.25 −1.10 0.30
NCOA3 −1.18 0.06 1.06 0.08 1.18 0.08 −1.17 0.06
NFKB1 −1.24 0.12 2.09 0.30 1.04 0.03 1.05 0.03
NFKB2 −1.25 0.09 2.52 0.29 −1.02 0.16 1.04 0.17
NFKBIA −1.11 0.08 3.55 0.31 1.05 0.12 1.47 0.17
NQO1 −1.27 0.09 −1.34 0.08 1.13 0.06 −1.14 0.04
NR4A2 1.09 0.19 1.11 0.19 −1.20 0.14 −1.40 0.12
PDGFB 1.02 0.11 1.28 0.14 −1.26 0.04 −1.12 0.04
PLAU −1.64 0.10 1.08 0.18 −1.09 0.20 −1.47 0.15
PTGS2 1.39 0.04 2.12 0.06 1.07 0.19 1.01 0.18
REL 1.11 0.15 1.84 0.25 1.02 0.05 −1.17 0.04
RELA 1.17 0.07 1.48 0.08 1.21 0.07 1.15 0.07
RELB −1.39 0.26 −1.09 0.33 1.01 0.19 −1.20 0.16
SELE −1.09 0.41 −1.34 0.33 −1.00 0.18 1.06 0.19
SELP 1.01 0.11 1.28 0.13 −1.26 0.04 −1.12 0.04
SNAP25 −1.74 0.14 −2.36 0.10 −1.32 0.24 −1.69 0.18
SOD2 −1.17 0.06 −1.06 0.06 1.24 0.12 1.29 0.13
STAT1 1.19 0.14 1.40 0.17 −1.01 0.04 −1.03 0.04
STAT3 −1.29 0.09 −1.32 0.09 1.11 0.07 −1.08 0.06
STAT5B −1.16 0.13 −1.18 0.13 −1.14 0.12 −1.40 0.10
TNF 1.08 0.12 6.72 0.76 −1.26 0.04 −1.12 0.04
TNFRSF1B 1.07 0.30 −2.04 0.14 2.88 1.60 −2.65 0.21
TNFSF10 1.06 0.27 −1.65 0.15 1.58 0.60 −2.19 0.17
TP53 −1.03 0.02 1.49 0.03 −1.12 0.02 −1.03 0.02
TRAF2 −1.13 0.09 1.32 0.14 −1.00 0.04 1.15 0.05
VCAM1 −1.77 0.15 −1.10 0.24 −1.26 0.04 −1.12 0.04
XIAP −1.01 0.12 1.19 0.14 −1.02 0.12 −1.32 0.09
ACTB 1.25 0.11 1.12 0.10 1.19 0.17 1.24 0.18
B2M −1.08 0.07 −1.01 0.08 −1.06 0.04 −1.07 0.04
GAPDH −1.02 0.05 −1.12 0.04 1.13 0.05 1.10 0.05
HPRT1 −1.10 0.04 −1.05 0.04 −1.21 0.11 −1.21 0.11
RPLP0 1.01 0.05 1.10 0.05 1.01 0.05 1.01 0.05
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